Cumulative Index

February–August

Page numbers of clinic titles are given in **boldface** type.

ABDOMINAL vs. vaginal delivery, *Aug.*, 593–4
Abnormalities. See also under organs and regions.
  chromosomal, genetic counseling in, *May*, 349
  congenital
    due to rubella, *May*, 258, 259
      frequency, *May*, 252
    genetic counseling in, *May*, 348, 349
  cytogenetic, in leukemia, *May*, 274
  neurologic. See *Neurologic abnormalities.*
  of transitional circulation, *Aug.*, 762–3
Abortion, therapeutic, in rubella, *May*, 261
Accelerated reaction to smallpox vaccination, *Feb.*, 91
Acetylcholine, effect on fetal lung, *Aug.*, 758, 759
Acid. See specific acids, as *Homovanillic acid*, etc.
Acid-base status
  and birth asphyxia, *Aug.*, 579–82
  correction for respiratory distress syndrome, *Aug.*, 721
  in newborn, effects of cold on, *Aug.*, 608
Acidemia in respiratory distress syndrome, *Aug.*, 721
Acidification of urine, *May*, 240
Acidosis. See also *Alkalosis.*
  fetal, *Aug.*, 580–82
  in premature infant, oxygen for, *Aug.*, 748–9
  lactic
    clinical features, *May*, 496
    infantile, familial, *May*, 491
      clinical features, *May*, 496
    with necrotizing encephalopathy, *May*, 491
ACTH. See *Corticotropin.*
Actinomycin C after renal transplantation, *May*, 393, 394
Activity, sympathetic, in newborn, *Aug.*, **863–77**
Adenoma, islet cell, hypoglycemia due to, *Aug.*, 912
Adenosine triphosphate metabolism in erythrocytes of newborn, *Aug.*, 885
Adrenal glands. See also *Corticotropin.*
  cortex
    insufficiency, after surgery for pheochromocytoma, *Feb.*, 16
Adrenal glands (*Continued*)
  cortex, steroids, for neural tumors with chronic diarrhea, *Feb.*, 13
  fetal
    corticosteroid content, *Feb.*, 61
    histochemical studies, *Feb.*, 63
    regulation, *Feb.*, 64–7
    steroid biosynthesis in, *Feb.*, 59–64
    studies in vitro, *Feb.*, 61–3
  hormones, and growth hormone, *May*, 447–8
  maturity, assessment of, *Aug.*, 857–8
Adrenalectomy for primary hyperaldosteronism, *Feb.*, 51
Adrenocortical insufficiency after surgery for pheochromocytoma, *Feb.*, 16
Adrenocorticosteroids for neural tumors with chronic diarrhea, *Feb.*, 13
Adrenogenital syndrome
  due to 3-beta-hydroxysteroid dehydrogenase deficiency, *May*, 489–90
    clinical features, *May*, 496
  hypoglycemia due to, *Aug.*, 911
Age
  effect on neonatal metabolism, *Aug.*, 613
  fetal, judgment of, *Aug.*, **823–62**
  gestational. See *Gestational age.*
  incidence of lymphocytic thyroiditis, *Feb.*, 26
Air. See also *Oxygen.*
  alveolar, partial pressure of gas in, in normal infant, *Aug.*, 735
Airway
  conductance, *Aug.*, 775
  resistance, *Aug.*, 774–8
Alae nasi, flaring in respiratory distress, *Aug.*, 683
Albinism, genetics, *May*, 339
Albumin. See also *Proteins.*
  serum, for prevention of respiratory distress syndrome, *Aug.*, 716
Aldosterone, *Feb.*, 43
  escape in hyperaldosteronism, *Feb.*, 50
  excretion, *Feb.*, 44
  production, *Feb.*, 44
  regulation, *Feb.*, 44–7
  secretion, *Feb.*, 44, 45, 46
    decreased, diseases with, *Feb.*, 54–6
    disorders of, *Feb.*, **43–58**
    increased, diseases with, *Feb.*, 47–54

Aldosteronism, congenital, *Feb.*, 48
Alkalosis. See also *Acidosis.*
hypokalemic, and hypertension with hypoaldosteronism, *Feb.*, 53
Alleles, *May*, 339
Allergic reactions to smallpox vaccination, *Feb.*, 91–2
Alveolar dead space, *Aug.*, 782, 791
Alveolar ventilation, *Aug.*, 782–4
Alveolar-arterial gas tensions, *Aug.*, 793
differences, *Aug.*, 791–4
measurements and interpretations, *Aug.*, 793–4
theory and methods, *Aug.*, 791–3
Alveolar-arterial oxygen differences, *Aug.*, 793
Alveoli, surface tension, reduction of, for respiratory distress syndrome, *Aug.*, 722
Amines, sympathomimetic, effect on neonatal metabolism, *Aug.*, 613
Amino acids. See also *Proteins;* and specific acids, as *Lysine;* etc.
metabolism in homocystinuria, *May*, 472
Ammonia intoxication, periodic. See under *Lysine intolerance.*
Amniotic fluid examination, *Aug.*, 592–3
Ampicillin
therapeutic use, *May*, 244, 245
in newborn, *May*, 538
Anatomic dead space, *Aug.*, 782
Anemia
fetal, asphyxia due to, *Aug.*, 585
hemolytic
in hemolytic-uremic syndrome, *May*, 298, 299
pathophysiology, *May*, 304–306
in newborn
associated with infections, *Aug.*, 887–8
autoimmune, *Aug.*, 899
glucose-6-phosphate dehydrogenase deficiency, *Aug.*, 894–6
Heinz body, *Aug.*, 889–90
nonspherocytic, congenital, *Aug.*, 893–4
related to defects in erythrocyte metabolism, *Aug.*, 888–97
unrelated to isoimmunization, *Aug.*, 886–99
of infancy, *Aug.*, 886
Anencephalic infant, steroids in, *Feb.*, 65
Anesthesia, regional, effect on fetus and newborn, *Aug.*, 590–91
Angle, popliteal, in newborn, *Aug.*, 826, 829
Anomalous pulmonary venous drainage, total, *Feb.*, 178–87
Anoxia. See *Asphyxia.*
Antibiotics. See also specific drugs, as *Penicillin;* etc.
for neuroblastoma, *Feb.*, 11
therapy, 1966, *May*, **231–50**
Antibodies
autoantibodies, thyroid, detection of, *Feb.*, 30
response to immunization, factors influencing, *Feb.*, 77–9
Antibodies (*Continued*)
response to poliovirus, *Feb.*, 94
thyroid, in lymphocytic thyroiditis, *Feb.*, 31
Antimetabolites
for neuroblastoma, *Feb.*, 11
in rubella, *May*, 262
Antimicrobials. See *Antibiotics; Drugs.*
Antitoxin, tetanus, *Feb.*, 87, 88
Aorta, coarctation, *Feb.*, 128–37
Aortic bodies, *Aug.*, 805–10
excitation, *Aug.*, 806
location, *Aug.*, 806
physiologic significance, *Aug.*, 806–809
response, *Aug.*, 806
Aortic stenosis, congenital, *Feb.*, 118–27
Apgar score, *Aug.*, 593, 635–6
and outcome of newborn, *Aug.*, **635–43**
birth weight and neurologic abnormality, *Aug.*, 638–40
inadequacy, *Aug.*, 645, 647
low, *Aug.*, 657–9
neonatal mortality and, *Aug.*, 636–8
reflections and advice, *Aug.*, **645–50**
relation to respiratory distress syndrome, *Aug.*, 673–4
timing, *Aug.*, 647
value, *Aug.*, 640–42
Apnea
neonatal, due to drugs administered to mother, *Aug.*, 589
primary, *Aug.*, 624
secondary, *Aug.*, 624
Apneic attacks, *Aug.*, 657
in newborn with low Apgar score, *Aug.*, 658–9
in respiratory distress, *Aug.*, 686, 687
Apneic pause, *Aug.*, 657
Apneic periods, oxygen for, *Aug.*, 744
Arterial oxygen tension; unsaturation. See under *Oxygen.*
Arterial-alveolar carbon dioxide pressure difference, *Aug.*, 791
Arteries. See also *Aorta; Blood pressure; Blood vessels; Ductus arteriosus; Thrombosis;* etc.
use for monitoring oxygen concentration, *Aug.*, 741, 742
Ascorbic acid for acidification of urine, *May*, 240
Asphyxia, *Aug.*, 579
birth
and acid-base status, *Aug.*, 579–82
effect on neonatal metabolism, *Aug.*, 615
brain damage and, *Aug.*, 631–2
cardiovascular responses during, *Aug.*, 624–7
clinical assessment, *Aug.*, 743
consequences, *Aug.*, 631
fetal and neonatal, causes, *Aug.*, 582–5
prevention, for prevention of respiratory distress syndrome, *Aug.*, 714–15
respiratory responses during, *Aug.*, 624–7
tolerance to, *Aug.*, 632
Aspiration, gastric, for prevention of respiratory distress syndrome, *Aug.*, 716

Asthmatics, metyrapone test in, *May*, 547, 551
Atelectasis of prematurity, *Aug.*, 705
ATP. See *Adenosine triphosphate.*
Atresia, tricuspid, *Feb.*, 208–17
Atrial septal defect, *Feb.*, 148–57
  ostium primum, *Feb.*, 168
  secundum type, *Feb.*, 148–57
Atrioventricular canal defects, *Feb.*, 168–77
Atropine
  effect on fetal heart rate, *Aug.*, 759
  maternal administration, effect on fetus, *Aug.*, 590
Autoantibodies, thyroid, detection of, *Feb.*, 30
Autoimmune hemolytic anemia in newborn, *Aug.*, 899
Autoimmunity, thyroid, in lymphocytic thyroiditis, *Feb.*, 22–5
Automatic walking in newborn, *Aug.*, 828, 829
Autosomal inheritance. See under *Inheritance.*
Azathioprine (Imuran)
  after renal transplantation, *May*, 391
  toxicity after renal transplantation, *May*, 396–7

BACITRACIN
  dosage, *May*, 233
  therapeutic use, *May*, 232–3
    in newborn, *May*, 535
Baroreceptor reflexes, sino-aortic, *Aug.*, 801–805
  excitation, *Aug.*, 802
  location, *Aug.*, 802
  physiologic significance, *Aug.*, 802–805
  response, *Aug.*, 802
Bartter's syndrome, *Feb.*, 53
Behavior
  delinquent, *May*, **459–68**. See also *Delinquency.*
  genetic factors in, *May*, 373–7
  nutritional factors in, *May*, 373–7
  sex differences in, *May*, 377
BEI. See *Iodine, butanol-extractable.*
BGH. See *Growth hormone, bovine.*
Bioassays of somatotropin, *May*, 440
Biopsy findings in lymphocytic thyroiditis, *Feb.*, 31, 32
Biosynthesis, steroid, in fetal adrenal, *Feb.*, 59–64
Birth. See also *Infants; Labor; Newborn; Premature infants.*
  asphyxia. See under *Asphyxia.*
  circulatory changes at, *Aug.*, 693–5
  heart rate after, *Aug.*, 761
  weight. See under *Weight.*
Bleeding. See *Hemorrhage.*
Blood. See also *Anemia; Hemoglobin;* etc.
  arterial and capillary, partial pressures of gases in, *Aug.*, 735
  cells, red. See *Erythrocytes.*
Blood (*Continued*)
  circulation
    changes at birth, *Aug.*, 693–5
    effect of stress and pharmacologic agents on, *Aug.*, 758–9
    fetal, *Aug.*, 755–8
      effect of stress and pharmacologic agents on, *Aug.*, 758–9
    hemodynamic changes
      fetal, during labor, *Aug.*, 576–9
      maternal, during labor, *Aug.*, 576
    perinatal, *Aug.*, **753–67**
    pulmonary. See *Lungs, blood flow.*
    transitional
      abnormalities, *Aug.*, 762–3
      normal, *Aug.*, 761–2
    uterine. See *Uterus, blood flow.*
  fetal
    oxygen saturation, *Aug.*, 757
    oxygen-carrying capacity, *Aug.*, 580
    oxygenation, *Aug.*, 754, 755
    sampling, *Aug.*, 592
  flow. See *Blood, circulation.*
  gases, *Aug.*, 794–6
  glucose values in newborn, *Aug.*, 907–909
  groups in organ transplantation, *May*, 383
  in hemolytic-uremic syndrome, *May*, 298–300
  pressure. See also *Hypertension; Hypotension.*
    in pheochromocytoma, *Feb.*, 14
  shunts
    capillary, *Aug.*, 791
    left-to-right, with increased pulmonary blood flow, *Aug.*, 695–6
    right-to-left, with reduced pulmonary blood flow, *Aug.*, 696–8
  sugar determinations
    in newborn, precautions, *Aug.*, 907
    methodology, *Aug.*, 906–907
  transfusion
    exchange
      for glucose-6-phosphate dehydrogenase deficiency, *Aug.*, 896
      for hemolytic anemia associated with infection, *Aug.*, 888
      for hereditary spherocytosis, *Aug.*, 892, 893
      for hyperbilirubinemia in infantile pyknocytosis, *Aug.*, 889
    for anemia
      in hemolytic-uremic syndrome, *May*, 306
      in hereditary spherocytosis, *Aug.*, 893
      in infantile pyknocytosis, *Aug.*, 889
    for pyruvate-kinase deficiency, *Aug.*, 896
    placental, and respiratory distress, *Aug.*, 628–31
  volume. See also *Heart, output.*
    capillary, pulmonary, *Aug.*, 789
Blood vessels. See also *Aorta; Arteries; Capillaries; Cardiovascular system; Veins;* etc.
  great, transposition of, *Feb.*, 198–207
  maturity, assessment of, *Aug.*, 859

Blood vessels (*Continued*)
resistance
and pulmonary blood flow, *Aug.*, 693–8
pulmonary, and blood flow in respiratory distress syndrome, *Aug.*, 695–8
Blue diaper syndrome, *May*, 478
clinical features, *May*, 494
Bodies
aortic, *Aug.*, 805–10
carotid, *Aug.*, 805–10
Heinz, *Aug.*, 883
Body
length
parent-child correlations, *May*, 355
relation to gestational age, *Aug.*, 851–2
sibling correlations, *May*, 354
position for prevention of respiratory distress syndrome, *Aug.*, 716
size, genetic and nutritional factors, *May*, 353–60
temperature. See under *Temperature.*
weight, relation to gestational age, *Aug.*, 849–51
Bones, epiphysial ossification, relation to gestational age, *Aug.*, 839
Bovine growth hormone, *May*, 448
Boyle's Law, *Aug.*, 780
Brain. See also *Head; Hypothalamus; Nervous system;* etc.
damage, asphyxia and, *Aug.*, 631–2
effect of oxygen on, *Aug.*, 740
involvement in homocystinuria, *May*, 471
weight, relation to gestational age, *Aug.*, 852–4
Breast nodule, size of, relation to gestational age, *Aug.*, 842, 843
Breathing. See also *Respiration.*
and resuscitation, onset, *Aug.*, **621–34**

CALCIUM
gluconate for hypocalcemia in hypoglycemia, *Aug.*, 916
metabolism, effect of somatotropin on, *May*, 446
restriction in hypercalcemia, *May*, 516
serum, in hypercalcemia, *May*, 510
Canal, atrioventricular, defects of, *Feb.*, 168–77
Capillaries. See also *Blood vessels.*
glomerular, fibrin thrombosis of, in hemolytic-uremic syndrome, *May*, 301
pulmonary, in respiratory distress syndrome, *Aug.*, 698–9
Capillary blood
glucose in newborn, *Aug.*, 908
volume, pulmonary, *Aug.*, 789
Capillary shunts, *Aug.*, 791
Carbocaine. See *Mepivacaine.*
Carbohydrates. See also *Glycogen;* etc.
metabolism, effect of somatotropin on, *May*, 446
Carbon dioxide pressure difference, arterial-alveolar, *Aug.*, 791
Carbon monoxide, pulmonary diffusing capacity, *Aug.*, 788–90
Carcinoma of thyroid, *Feb.*, 19
Cardiac. See *Heart.*
Cardiopulmonary adaptation, postnatal, integrated, *Aug.*, 794–6
Cardiovascular and respiratory reflexes in newborn, *Aug.*, **801–21**
Cardiovascular system. See also *Arteries; Blood vessels; Capillaries; Heart; Veins;* etc.
adjustments
in newborn, *Aug.*, 764–5
maternal, in pregnancy, *Aug.*, 753–4
lesions in hypercalcemia, *May*, 511–13
responses during asphyxia and resuscitation, *Aug.*, 624–7
Carotid bodies, *Aug.*, 805–10
excitation, *Aug.*, 806
location, *Aug.*, 806
physiologic significance, *Aug.*, 806–809
response, *Aug.*, 806
Carotid sinus massage, *Aug.*, 804
Cartilaginous development of earlobe, relation to gestational development, *Aug.*, 844, 845
Catecholamines, *Feb.*, 3–4
effect on pulmonary function in newborn, *Aug.*, 866
excretion
in neural tumors with chronic diarrhea, *Feb.*, 13
in neuroblastoma, *Feb.*, 8, 11
in pheochromocytoma, *Feb.*, 15
metabolism in neuroblastoma, *Feb.*, 9
sympathetic activity, *Aug.*, 864
in fetus, *Aug.*, 864, 865
in placenta, *Aug.*, 864, 865
Cells
blood, red. See *Erythrocytes.*
number, relation to gestational age, *Aug.*, 854–5
reticulum, sarcoma, vs. neuroblastoma, *Feb.*, 7
size, relation to gestational age, *Aug.*, 854–5
Central nervous system, effects of cytomegalovirus infection on, *May*, 283–5
Cephalothin (Keflin)
dosage, *May*, 234
therapeutic use, *May*, 233–4
Cesarean section, respiratory difficulties due to, *Aug.*, 593
Chemicals, leukemia due to, *May*, 270
Chemoreceptor reflexes, *Aug.*, 805–14
Chemoreceptors
central, *Aug.*, 785–8, 811–14
excitation, *Aug.*, 811
location, *Aug.*, 811
physiologic significance, *Aug.*, 811–14
response, *Aug.*, 811
peripheral, *Aug.*, 785–8
Chemotherapy
for ganglioneuroblastoma, *Feb.*, 12
for neuroblastoma, *Feb.*, 9, 10, 11
Chest. See *Thorax.*

Child-rearing, defects in, delinquency due to, *May*, 463–6
Chloramphenicol
dosage, *May*, 236
therapeutic use, *May*, 234–6
in newborn, *May*, 535
Choreo-athetosis, mental deficiency and self-mutilation, hyperuricemia with, *May*, 486, 495
Chromosomes. See also *Genetics; Heredity.*
abnormalities, genetic counseling in, *May*, 349
normal number, *May*, 338
Circulation. See under *Blood.*
Circulatory effects of hyperkalemia in newborn, *Aug.*, 763–4
Citrullinemia, *May*, 485–6
clinical features, *May*, 495
Clamping of umbilical cord, delayed, for prevention of respiratory distress syndrome, *Aug.*, 715–16
Clinical advances, recent, symposium on, *May*, **229–541**
Clonal selection theory, *Feb.*, 23
Cloxacillin (Tego Pen), therapeutic use, *May*, 242, 243
Coarctation of aorta, *Feb.*, 128–37
Cold. See also *Temperature.*
and resuscitation, *Aug.*, 627–8
effects
on acid-base state in newborn, *Aug.*, 608
on neonatal metabolism, *Aug.*, 616–17
exposure of newborn to, effects, *Aug.*, 616
Colistimethate
therapeutic use, *May*, 245, 246
in newborn, *May*, 536
Colistin. See *Colistimethate.*
Colon, malrotation, congenital, genetic counseling in, *May*, 346
Compliance
pulmonary. See *Lungs, compliance.*
thoracic cage, *Aug.*, 771
Conductance, airway, *Aug.*, 775
Conduction, dissipation of thermal energy by, *Aug.*, 603
Congenital abnormalities due to rubella, *May*, 258, 259
Congenital aortic stenosis, *Feb.*, 118–27
Congenital defects due to rubella, frequency, *May*, 252
Congenital heart disease, operable, *Feb.*, **105–219**
Convection, dissipation of thermal energy by, *Aug.*, 603
Convulsions in newborn with low Apgar scores, *Aug.*, 658–9
Cooling, effect on neonatal metabolism, *Aug.*, 611, 612
Cord, umbilical. See *Umbilical cord.*
Corticosteroids
biosynthesis in fetal adrenal, *Feb.*, 59–64
conversions in fetal adrenal, *Feb.*, 61
fetal, role of, *Feb.*, 67–8
for neural tumors with chronic diarrhea, *Feb.*, 13
for neuroblastoma, *Feb.*, 11
Corticosteroids (*Continued*)
in anencephalic infant, *Feb.*, 65
in cytomegalovirus infection, *May*, 290
in fetal adrenals, *Feb.*, 61
in umbilical cord plasma, measurement, *Feb.*, 63–4
labeled, perfusion of fetus, *Feb.*, 64
maternal, placental transport of, *Feb.*, 68–9
Corticotropin (ACTH) for hypoglycemia, *Aug.*, 916
Corticotropin-cortisol insufficiency
avoidance of, *May*, 553–5
iatrogenic, duration of, *May*, **543–57**
Cortisol. See *Hydrocortisone.*
Cortisone in hypercalcemia, *May*, 517
Counseling, genetic, *May*, **337–52**
Craniosynostosis in hypercalcemia, *May*, 509
Creases, skin, on sole of foot, relation to gestational age, *Aug.*, 842
Creatinine, urinary, in ACTH-cortisol insufficiency, *May*, 545
Cry in newborn, *Aug.*, 829
Crying vital capacity, *Aug.*, 779
Cyanosis
in respiratory difficulty, *Aug.*, 671
in respiratory distress, *Aug.*, 685
Cyclophosphamide for neuroblastoma, *Feb.*, 11
Cystathionine metabolism in homocystinuria, *May*, 471
Cystinlysinuria, *May*, 486
Cytogenetic abnormalities in leukemia, *May*, 274
Cytomegalic inclusion disease, *May*, 279
etiology, *May*, 280–81
Cytomegaloviruses. See under *Viruses.*

Deafness, congenital, genetic causes, *May*, 344
Death after renal transplantation, causes of, *May*, 396
Defects. See *Abnormalities.*
Delinquency, *May*, 459–68
as manifestation of psychotic illness, *May*, 466-7
as response to physical handicap, *May*, 462–3
extent of problem, *May*, 459–60
gang, *May*, 460–61
individual, *May*, 461–7
resulting from defects in rearing process, *May*, 463–6
resulting from developmental retardation, *May*, 461–2
sociologic, *May*, 460–61
types, *May*, 460–67
Delinquent behavior, *May*, **459–68**. See also *Delinquency.*
Delivery. See also *Labor.*
abdominal, vs. vaginal delivery, *Aug.*, 593–4
effects on fetal heart rate, *Aug.*, 759–61

Delivery (*Continued*)
fetal heart rate during, *Aug.*, 653
mode of, for prevention of respiratory distress syndrome, *Aug.*, 715
reaction of newborn to, *Aug.*, 652–6
reactivity of newborn after, *Aug.*, 655, 656
relation to respiratory distress syndrome, *Aug.*, 674–5
room
care, *Aug.*, 665–6
routine, modification of, *Aug.*, 664–7
sensory input to fetus during, *Aug.*, 652
vaginal, vs. abdominal delivery, *Aug.*, 593–4
Dental. See *Teeth.*
Dermatitis as contraindication to smallpox vaccination, *Feb.*, 92
Desoxycorticosterone (DOC) for hypoaldosteronism, *Feb.*, 56
Development. See also *Growth.*
behavioral, genetic and nutritional factors in, *May*, 373–7
dental, genetic and nutritional factors, *May*, 367–73
growth and, interaction of nutrition and genetics in timing of, *May*, **353–79**
retardation in, delinquency due to, *May*, 461–2
skeletal. See under *Skeleton.*
Dextran in hemolytic-uremic syndrome, *May*, 307
Diabetes mellitus with thyroditis, *Feb.*, 32
Diabetic mothers, infants of, hypoglycemia in, *Aug.*, 912–13
Diagnosis in genetic counseling, *May*, 343–6
Dialysis, peritoneal, in hemolytic-uremic syndrome, *May*, 306
Diaper, blue, syndrome of. See *Blue diaper syndrome.*
Diarrhea, chronic, neural tumors and, *Feb.*, 13
Dicloxacillin, therapeutic use, *May*, 243
Diet. See also *Nutrition.*
in hypercalcemia, *May*, 516–17
Diffusion, pulmonary, *Aug.*, 788–90
Digitalization, early, for prevention of respiratory distress syndrome, *Aug.*, 717
Dihydroxy-phenylalanine (DOPA) excretion, *May*, 479–80
clinical features, *May*, 494
Diphenicillin, therapeutic use, *May*, 243
Diphtheria immunization, *Feb.*, 81, 84–6
Disease. See also *Death; Diagnosis; Health;* etc.
cytomegalic inclusion. See *Cytomegalic inclusion disease.*
determinants, *May*, 316–18
etiology, psychologic factors in, *May*, 318–20
genetic, before onset of leukemia, *May*, 272–3
Hartnup. See *Hartnup disease.*
Hashimoto's, *Feb.*, 19, 20, 32
heart. See under *Heart.*
hyaline membrane, and intracranial hemorrhage, *Aug.*, 688
Disease (*Continued*)
infectious. See *Infectious disease.*
intrinsic, in newborn, *Aug.*, 664
oasthouse urine, *May*, 473
pink, *Aug.*, 869
psychogenic, *May*, 319
Quervain's, *Feb.*, 20
sickle cell, in newborn, *Aug.*, 898
with decreased aldosterone secretion, *Feb.*, 54–6
with increased aldosterone secretion, *Feb.*, 47–54
Disorders
due to sympathetic overactivity, *Aug.*, 869
genetic. See *Genetic disorders.*
of aldosterone secretion, *Feb.*, **43–58**
Distress
fetal, relief of, *Aug.*, 585–9
respiratory. See *Respiratory distress.*
Diuresis after renal transplantation, *May*, 391
DOC. See *Desoxycorticosterone.*
Donor selection for renal transplantation, *May*, 383–5
DOPA. See *Dihydroxy-phenylalanine.*
Dopamine, *Feb.*, 3, 4
excretion
in neuroblastoma, *Feb.*, 9
in pheochromocytoma, *Feb.*, 15
Down's syndrome, leukemia and, *May*, 272
Drainage, pulmonary venous, anomalous, total, *Feb.*, 178–87
Drugs. See also names of drugs.
absorption in newborn, *May*, 528–9
administration to mother
effect on fetus, *Aug.*, 589
effect on newborn, *Aug.*, 659–62
distribution in newborn, *May*, 529–31
dosage for newborn, *May*, 534, 535
effect on blood flow, *Aug.*, 758–9
effect on neonatal metabolism, *Aug.*, 615
excretion in newborn, *May*, 533–4
metabolism in newborn, *May*, 531–3
protein binding, *May*, 530
Ductus arteriosus
closure, *Aug.*, 762
patent, *Feb.*, 138–47
Dwarfism
congenital tryptophanuria with, *May*, 478
pituitary, somatotropin for, *May*, 449, 450
Dynamic compliance, *Aug.*, 773
Dynamics, *Aug.*, 770
pulmonary, *Aug.*, 774–8
Dyspnea. See also *Respiration.*
in respiratory difficulty, *Aug.*, 671
Dystrophy, muscular, *May*, 492–3
clinical features, *May*, 496

EAR. See also *Deafness.*
oximeters for measurement of oxygen concentration, *Aug.*, 742
Earlobe, cartilaginous development, relation to gestational age, *Aug.*, 844, 845

Ectopia lentis in homocystinuria, *May*, 469, 471
Eczema
as contraindication to smallpox vaccination, *Feb.*, 92
vaccinatum, *Feb.*, 93
Edema in respiratory distress, *Aug.*, 685
Elbow, skeletal development, *May*, 366
Electrocardiogram
fetal, *Aug.*, 592
in aortic stenosis, *Feb.*, 121
in atrial septal defect, *Feb.*, 151
in coarctation of aorta, *Feb.*, 131
in endocardial cushion defects, *Feb.*, 171
in hyperkalemia in newborn, *Aug.*, 764
in patent ductus arteriosus, *Feb.*, 141
in pulmonary stenosis, *Feb.*, 111
in tetralogy of Fallot, *Feb.*, 191
in transposition of great vessels, *Feb.*, 201
in transposition of pulmonary veins, *Feb.*, 181
in tricuspid atresia, *Feb.*, 211
in ventricular septal defect, *Feb.*, 161
Electroencephalograms
effect of hypoglycemia on, *Aug.*, 916
in newborn, *Aug.*, 828–32
Elfin facies in hypercalcemia, *May*, 507
Embryonic characteristics of erythrocytes of newborn, *Aug.*, 880–81
Embryopathy, rubella, prophylaxis of, *May*, 260–63
Encephalitis, postvaccinal, *Feb.*, 93
Encephalopathy, necrotizing, lactic acidosis with, *May*, 491, 496
Endocardial cushion defects, *Feb.*, 168–77
Endocrine relations, fetal-placental, *Feb.*, 67–9
Enema, magnesium sulfate, for respiratory distress syndrome, *Aug.*, 722
Energy
substrates in newborn, *Aug.*, 867–8
thermal. See *Thermal energy.*
Enthalpy, *Aug.*, 600
Environment
intrauterine
abnormal, effects on newborn, *Aug.*, 662–4
normal, *Aug.*, 754–5
thermal, neutral, *Aug.*, 600, 807
Environmental temperature, *Aug.*, 601
neutral, *Aug.*, 600
Enzymes
activity in erythrocytes of newborn, *Aug.*, 882, 883
in drug metabolism, *May*, 532
induction in newborn, *May*, 533
Epinephrine, *Feb.*, 3, 4
effects
on pulmonary function in newborn, *Aug.*, 866
on respiratory distress syndrome, *Aug.*, 872, 873
excretion in pheochromocytoma, *Feb.*, 15
infusion, effects of, *Aug.*, 869–70
release
hypercapnia and, *Aug.*, 871–2
Epinephrine (*Continued*)
release, hypoxia and, *Aug.*, 870–71
sympathetic activity, *Aug.*, 864
in fetus, *Aug.*, 864, 865
in placenta, *Aug.*, 864, 865
Epiphyses, ossification, relation to gestational age, *Aug.*, 839
Erythrocytes. See also *Anemia; Hemoglobin;* etc.
effect of oxygen on, *Aug.*, 740–41
embryonic characteristics in newborn, *Aug.*, 880–81
hemolysis and metabolism, in newborn, *Aug.*, **879–903**
in hemolytic-uremic syndrome, *May*, 299
integrity, maintenance in newborn, *Aug.*, 883–4
metabolism
and hemolysis in newborn, *Aug.*, **879–903**
hemolytic anemias in newborn, related to defects in, *Aug.*, 888–97
in newborn, *Aug.*, 881–5
inborn errors, early manifestations of, *Aug.*, 891–7
survival in newborn, *Aug.*, 885
Erythromycin
therapeutic use, *May*, 236
in newborn, *May*, 536
Estriol excretion as index of fetal viability, *Feb.*, 68
Estrogens
estriol excretion as index of fetal viability, *Feb.*, 68
production, fetal role in, *Feb.*, 67
Ethical issues in renal transplantation, *May*, 386–7
Euthyroid child, goiter in, *Feb.*, 26
Evaporation, dissipation of thermal energy by, *Aug.*, 603
Ewing's tumor vs. neuroblastoma, *Feb.*, 7
Exanthems, viral, glucocorticoid therapy during, *May*, 555
Expansion, pulmonary, stability of, relation to survival time, *Aug.*, 704
Expiratory reserve volume, *Aug.*, 778
Extension, crossed, in newborn, *Aug.*, 828, 829
Eyes
involvement in homocystinuria, *May*, 471
retrolental fibroplasia. See *Retrolental fibroplasia.*

FACIES, elfin, in hypercalcemia, *May*, 507
Fallot, tetralogy of, *Feb.*, 188–97
Familial hypolipidemia, *May*, 478
Familial infantile lactic acidosis. See under *Acidosis.*
Family history in genetic disorders, *May*, 344–5
Fat
brown, as source of heat production, *Aug.*, 603
metabolism in newborn, *Aug.*, 867

Feeding
in respiratory distress syndrome, *Aug.*, 721–2
of newborn with low Apgar scores, *Aug.*, 659
Fetal factors in asphyxia, *Aug.*, 584–5
Fetal hemoglobin, *Aug.*, 880
Fetal life, role of thermal factors in, *Aug.*, **599–619**
Fetal-placental endocrine relations, *Feb.*, 67–9
Fetal-placental-maternal interrelations involving steroid hormones, *Feb.*, **59–73**
Fetus. See also *Labor; Newborn; Placenta; Pregnancy; Umbilical cord;* etc.
acidosis, *Aug.*, 580–82
adrenal glands. See *Adrenal glands, fetal.*
age
clinical significance of gestational age, *Aug.*, **835–48**
judgment of, *Aug.*, **823–62**
neurologic evaluation, *Aug.*, **823–33**
pathologist's evaluation, *Aug.*, **849–62**
asphyxia, causes of, *Aug.*, 582–5
blood. See *Blood, fetal.*
coarctation of aorta, *Feb.*, 129, 131
condition, evaluation of, *Aug.*, 592–3
distress, relief of, *Aug.*, 585–9
effect of drugs administered to mother, *Aug.*, 589
effect of pain relief on, *Aug.*, 589–91
electrocardiography, *Aug.*, 592
heart rate. See *Heart rate, fetal.*
hemodynamic changes during labor, *Aug.*, 576–9
influence of labor on, *Aug.*, **575–98**
malnutrition, relation to gestational age, *Aug.*, 836, 838
oxygenation, *Aug.*, 579–80
perfusion with labeled steroids, *Feb.*, 64
pulmonary fluid in, *Aug.*, 621–2
risk of rubella to, *May*, 251–2
sensory input during labor and delivery, *Aug.*, 652
steroids, role of, *Feb.*, 67–8
sympathetic activity in, *Aug.*, 864–5
tachycardia, *Aug.*, 760
thermoregulation, *Aug.*, 603–604
viability, estriol excretion as index of, *Feb.*, 68
Fibrin thrombosis of glomerular capillaries in hemolytic-uremic syndrome, *May*, 301
Fibrinolysin for respiratory distress syndrome, *Aug.*, 722–3
Fibroplasia, retrolental. See *Retrolental fibroplasia.*
Flow, blood. See *Blood, circulation.*
Fluids
amniotic, examination of, *Aug.*, 592–3
pulmonary, in fetus, *Aug.*, 621–2
therapy, parenteral
early use in newborn, *Aug.*, 666
in chronic diarrhea with neural tumor, *Feb.*, 13
Fluoride in lactic acidosis with necrotizing encephalopathy, *May*, 491
Fluorohydrocortisone for hypoaldosteronism, *Feb.*, 56
Foetopathia diabetica, *Aug.*, 912
Foot
skeletal development, *May*, 366
skin creases on sole, relation to gestational age, *Aug.*, 842
Foramen ovale, closure, *Aug.*, 762
Formiminotransferase deficiency syndrome, *May*, 490–91
clinical features, *May*, 496
Formula, meat-base, in hypercalcemia, *May*, 516
Fructose
for hypoglycemia in infants of diabetic mothers, *Aug.*, 913
intolerance, hereditary, hypoglycemia due to, *Aug.*, 911
Furadantin. See *Nitrofurantoin.*

GALACTOSEMIA, hypoglycemia due to, *Aug.*, 911
Gamma globulin
for measles vaccination, *Feb.*, 99
immune, for vaccinia, *Feb.*, 92
in rubella, *May*, 260–61
tetanus, *Feb.*, 88, 89
Gang delinquency, *May*, 460–61
Ganglioneuroblastoma, *Feb.*, 12
Ganglioneuroma, *Feb.*, 12
Gases
blood, *Aug.*, 794–6
in alveolar air and arterial and capillary blood, partial pressures, Aug., 735
tension
alveolar-arterial, *Aug.*, 793
differences, alveolar-arterial, *Aug.*, 791–4
volume, thoracic, *Aug.*, 780
Gastric. See *Stomach.*
Genes, *May*, 339. See also *Heredity.*
dominance
incomplete, *May*, 341
vs. recessivity, *May*, 339–41
strength, *May*, 339–41
Genetic counseling, *May*, **337–52**
Genetic disorders
etiology, *May*, 344, 345–6
family history, *May*, 344–5
Genetics. See also *Chromosomes; Heredity.*
and nutrition, interaction of, in timing of growth and development, *May*, **353–79**
leukemia and, *May*, 272–4
problems, *May*, 343
Genotype, *May*, 339
Gestational age
assessment methods
clinical, *Aug.*, 841–5
experience with, *Aug.*, 845–6
evaluation of, *Aug.*, 839
clinical significance, *Aug.*, 836–9
and method for assessment, *Aug.*, 835–48
relation to respiratory distress syndrome, *Aug.*, 675–6

Glands, adrenal. See *Adrenal glands.*
Globulin, gamma. See *Gamma globulin.*
Glomeruli, capillaries, fibrin thrombosis of, in hemolytic-uremic syndrome, *May,* 301
Glomerulonephritis. See *Nephritis, glomerular.*
Glucocorticoids
ACTH-cortisol insufficiency due to, *May,* 544–5, 547, 552
postoperative use in primary hyperaldosteronism, *Feb.,* 51
therapy
duration, *May,* 555
during viral exanthems, *May,* 555
effect on symptoms of disease, *May,* 554
in stress, *May,* 555
intermittent, *May,* 553
tapering, *May,* 553–4
topical, *May,* 555
with ACTH therapy, *May,* 553
Glucose
blood, values in newborn, *Aug.,* 907–909
for acidemia in respiratory distress syndrome, *Aug.,* 721
for hyperkalemia in newborn, *Aug.,* 764
for hypoglycemia, *Aug.,* 915, 916
for relief of fetal distress, *Aug.,* 588
metabolism in erythrocytes of newborn, *Aug.,* 881
Glucose-6-phosphate dehydrogenase deficiency
clinical manifestations, *Aug.,* 895
in newborn, *Aug.,* 894–6
Glutathione peroxidase deficiency in erythrocytes of newborn, *Aug.,* 883, 884
Glycinemia
clinical features, *May,* 494
with hypo-oxaluria, clinical features, *May,* 494
Glycogen
storage disease, hypoglycemia due to, *Aug.,* 911
synthetase deficiency, hypoglycemia due to, *Aug.,* 911
Glycolysis in erythrocytes of newborn, *Aug.,* 881–2
Goiter. See also *Thyroid.*
in euthyroid child, *Feb.,* 26
in lymphocytic thyroiditis, *Feb.,* 26–7
Gonadal steroids, role in growth and sexual function, *May,* 432–3
Gonadotropin secretion, control of, *May,* 427–8
Grasp
prehensile, abnormal, *Aug.,* 640
reflex in newborn, *Aug.,* 827, 829
Gray syndrome, *May,* 235, 535
Great vessels, transposition, Feb., 198–207
Growth. See also *Development; Diet; Dwarfism; Nutrition;* etc.
and development, interaction of nutrition and genetics in timing of, *May,* **353–79**
effect of somatotropin on, *May,* 444–5
failure, somatotropin for, *May,* 451
hormone. See *Somatotropin.*
bovine, *May,* 448
Growth (*Continued*)
neuroendocrine regulation, *May,* 423–36
promotion, protein synthesis in, *May,* 445
skeletal, relation to gestational age, *Aug.,* 839, 840
sympathetic activity in, *Aug.,* 868

HAIR on head, relation to gestational age, *Aug.,* 843, 844
Hand, skeletal development, *May,* 366
Handicap, physical, delinquency due to, *May,* 462–3
Hartnup disease, *May,* 476–7
clinical features, *May,* 494
Hashimoto's disease, *Feb.,* 19, 20, 32
Head. See also *Brain.*
circumference, relation to gestational age, *Aug.,* 852–4
hair, relation to gestational age, *Aug.,* 843, 844
Head's reflex, *Aug.,* 814, 815
Health. See also *Disease.*
public, considerations in hypercalcemia, *May,* 522–3
Heart. See also *Blood circulation; Cardiovascular system; Myocardium;* etc.
catheterization
in aortic stenosis, *Feb.,* 124
in atrial septal defect, *Feb.,* 154
in coarctation of aorta, *Feb.,* 134
in endocardial cushion defects, *Feb.,* 174
in patent ductus arteriosus, *Feb.,* 144
in pulmonic stenosis, *Feb.,* 114
in tetralogy of Fallot, *Feb.,* 194
in transposition of great vessels, *Feb.,* 204
in transposition of pulmonary veins, *Feb.,* 184
in tricuspid atresia, *Feb.,* 214
in ventricular septal defect, *Feb.,* 164
disease, congenital
clinical classification, *Feb.,* 218
operable, *Feb.,* **105–219**
physiologic classification, *Feb.,* 218
massage for asphyxia, *Aug.,* 625
maturity, assessment of, *Aug.,* 856
murmurs and sounds
in hypercalcemia, *May,* 509, 511
in newborn, *Aug.,* 764
in respiratory distress, *Aug.,* 684
output
in newborn, *Aug.,* 764
in pregnancy, *Aug.,* 753, 754
rate
after birth, *Aug.,* 761
fetal
and effects of stress, labor and delivery, *Aug.,* 759–61
during delivery, *Aug.,* 653
during labor, *Aug.,* 576–9, 653
effects of stress, labor and delivery on, *Aug.,* 759–61
in respiratory distress, *Aug.,* 677 ff.

Heat, *Aug.*, 600. See also *Temperature.*
effect on neonatal metabolism, *Aug.*, 611, 612
loss in newborn, *Aug.*, 605
production. See also *Metabolism.*
in newborn. See under *Newborn.*
measurement of, *Aug.*, 602
Heel-to-ear maneuver in newborn, *Aug.*, 826, 829
Height, parent-specific standards, *May*, 357, 358
Heinz body anemia in newborn, *Aug.*, 889–90
Heinz bodies, *Aug.*, 883
Hematopoiesis, maturity, assessment of, *Aug.*, 858–9
Hemodynamic. See under *Blood, circulation.*
Hemoglobin. See also *Anemia; Blood; Erythrocytes.*
fetal, *Aug.*, 880
oxygen binding, *Aug.*, 733
Hemoglobinopathies in newborn, *Aug.*, 898
Hemolytic anemia. See under *Anemia.*
Hemolytic-uremic syndrome, *May*, **295–314**
Hemophilia A, genetics, *May*, 342
Hemorrhage
in hemolytic-uremic syndrome, *May*, 300
intracranial, and hyaline membrane disease, *Aug.*, 688
Heparin
for tissue preservation in renal transplantation, *May*, 387
in hemolytic-uremic syndrome, *May*, 307
Hepatic. See *Liver.*
Herd immunity, *Feb.*, 95
Hereditary fructose intolerance, hypoglycemia due to, *Aug.*, 911
Hereditary spherocytosis, neonatal manifestations, *Aug.*, 891–3
Heredity. See also *Chromosomes; Genetics;* etc.
autosomal, *May*, 341–2
vs. sex-linked, *May*, 341–3
genetic problem, *May*, 343
in lymphocytic thyroiditis, *Feb.*, 33
physical basis, *May*, 338–41
sex-linked, *May*, 342–3
Hering-Breuer reflexes, *Aug.*, 815
Hetacillin, therapeutic use, *May*, 245
HGH. See *Somatotropin.*
Hip, skeletal development, *May*, 366
Histamine, effect on fetal lung, *Aug.*, 758
Histochemical studies on fetal adrenal tissue, *Feb.*, 63
Histocompatibility tests in renal transplantation, *May*, 385–6
History
family, in genetic disorders, *May*, 344–5
in aortic stenosis, *Feb.*, 120
in atrial septal defect, *Feb.*, 150
in coarctation of aorta, *Feb.*, 130
in endocardial cushion defects, *Feb.*, 170
in patent ductus arteriosus, *Feb.*, 140
in pulmonic stenosis, *Feb.*, 110
in tetralogy of Fallot, *Feb.*, 190
in transposition of great vessels, *Feb.*, 200
History (*Continued*)
in transposition of pulmonary veins, *Feb.*, 180
in tricuspid atresia, *Feb.*, 210
in ventricular septal defect, *Feb.*, 160
Homocystinuria, *May*, 469–72
clinical features, *May*, 494
Homoiothermy, *Aug.*, 601
Homovanillic acid, *Feb.*, 4
excretion
in neuroblastoma, *Feb.*, 9
in pheochromocytoma, *Feb.*, 15
Hooke's Law, *Aug.*, 770
Hormones
growth. See *Somatotropin.*
steroid, fetal-placental-maternal interrelations involving, *Feb.*, 59–73
thyroid, role in growth and sexual function, *May*, 433
Humidity for respiratory distress syndrome, *Aug.*, 717–18
HVA. See *Homovanillic acid.*
Hurler's syndrome, genetic causes, *May*, 344
Hyaline membranes
disease, intracranial hemorrhage and, *Aug.*, 688
relation to survival time, *Aug.*, 704
Hydrocortisone (cortisol), *Feb.*, 44
biosynthesis, *Feb.*, 61
for adrenocortical insufficiency after surgery for pheochromocytoma, *Feb.*, 16
for hypoaldosteronism, *Feb.*, 56
for hypoglycemia, *Aug.*, 916
Hydrocortisone-ACTH insufficiency, iatrogenic, duration of, *May*, **543–57**
Hydroxycorticosteroids, urinary, in ACTH-cortisol insufficiency, *May*, 545–6, 547
Hydroxykynureninuria, *May*, 479
clinical features, *May*, 494
Hydroxyprolinemia, *May*, 487–8
clinical features, *May*, 495
Hydroxysteroid dehydrogenase deficiency, adrenogenital syndrome due to, *May*, 489–90
Hyperaldosteronism
classification, *Feb.*, 47
juvenile, *Feb.*, 48
primary, *Feb.*, 47–51
vs. secondary hyperaldosteronism, *Feb.*, 52, 53
secondary, *Feb.*, 51–3
vs. primary hyperaldosteronism, *Feb.*, 50, 51
symptoms and signs, *Feb.*, 49
Hyperammoniemia, *May*, 485
Hyperbaric oxygen. See under *Oxygen.*
Hyperbilirubinemia complicating respiratory distress syndrome, *Aug.*, 724–5
Hypercalcemia, infantile, *May*, **503–25**
cardiovascular lesions, *May*, 511–13
mild, *May*, 504–506
public health considerations, *May*, 522–3
severe, *May*, 506–509
late normocalcemic stage, *May*, 513–15
Hypercapnia, epinephrine release and, *Aug.*, 871–2

Hyperglycinemia, *May*, 474–5
with hypo-oxaluria, *May*, 474–5
Hyperkalemia
circulatory effects in newborn, *Aug.*, 763–4
in respiratory distress syndrome, *Aug.*, 721
Hyperlysinemia, *May*, 483–4
clinical features, *May*, 495
Hypermethioninemia, *May*, 472–3
clinical features, *May*, 494
Hyperplasia, thyroid, in lymphocytic thyroiditis, *Feb.*, 21
Hyperprolinemia, *May*, 486–7
Hypersarcosinemia, *May*, 475–6
Hypertension. See also *Blood pressure.*
and hypokalemic alkalosis with hypoaldosteronism, *Feb.*, 53
in pheochromocytoma, *Feb.*, 14
Hyperuricemia with choreo-athetosis, mental deficiency and self-mutilation, *May*, 486
clinical features, *May*, 495
Hypervalinemia, *May*, 483
clinical features, *May*, 495
Hypervolemia, *Aug.*, 805
Hypoaldosteronism, *Feb.*, 54, 55
hypokalemic alkalosis and hypertension with, *Feb.*, 53
treatment, *Feb.*, 56
Hypoglycemia, *Aug.*, 905, 909
clinical manifestations, *Aug.*, 909–10
differential diagnosis, *Aug.*, 910–15
effect on somatotropin secretion, *May*, 439
idiopathic, *Aug.*, 912
in newborn, *Aug.*, **905–20**
persistent, *Aug.*, 911–12
prognosis, *Aug.*, 916–17
somatotropin for, *May*, 451–2
symptomatic, transient, *Aug.*, 913–15
pathogenesis, *Aug.*, 914
transient, *Aug.*, 912–15
treatment, *Aug.*, 915–16
Hypokalemic alkalosis and hypertension with hypoaldosteronism, *Feb.*, 53
Hypolipidemia, familial, *May*, 478
Hypo-oxaluria, hyperglycinemia with, *May*, 474–5
clinical features, *May*, 494
Hypotension. See also *Blood pressure.*
fetal, asphyxia due to, *Aug.*, 584, 585
maternal, fetal and neonatal asphyxia due to, *Aug.*, 583
Hypothalamic-pituitary unit, function, *May*, 428–32
Hypothalamus, *May*, 428, 429
role in growth hormone secretion, *May*, 434
role in precocious puberty, *May*, 426–7
Hypothermia. See *Cold.*
Hypothyroidism, *Feb.*, 25
Hypotonia in respiratory distress, *Aug.*, 685, 686
Hypovolemia, *Aug.*, 805
Hypoxia. See also *Asphyxia.*
clinical assessment, *Aug.*, 743
effects
in respiratory distress syndrome, *Aug.*, 718
Hypoxia (*Continued*)
effects on neonatal metabolism, *Aug.*, 614
epinephrine release and, *Aug.*, 870–71
maternal, fetal and neonatal asphyxia due to, *Aug.*, 582–3
responses of newborn to, *Aug.*, 737, 738

IATROGENIC ACTH-cortisol insufficiency, duration, *May*, **543–57**
Idiopathic respiratory distress syndrome, *Aug.*, 672–89
Immature infant, *Aug.*, 656–7
Immaturity, immunologic, *Feb.*, 78
Immunity. See also *Antibodies.*
autoimmunity, thyroid, in lymphocytic thyroiditis, *Feb.*, 22–5
durable, due to poliovirus vaccine, *Feb.*, 97
herd, *Feb.*, 95
to poliomyelitis, rapidity after vaccination, *Feb.*, 94–5
Immunization, *Feb.*, 75–104
active, schedule for, *Feb.*, 79–99
antibody response to, *Feb.*, 77–9
current concepts, *Feb.*, **75–104**
diphtheria, *Feb.*, 81, 84–6
general considerations, *Feb.*, 77–9
measles, *Feb.*, 81, 98–9
passive, *Feb.*, 77
pertussis, *Feb.*, 81, 82–4
poliomyelitis, *Feb.*, 81, 93–8, 99–102
rubella, *May*, 262
smallpox, *Feb.*, 81, 89–93
tetanus, *Feb.*, 81, 86–9
Immunoassays of somatotropin, *May*, 440–42
Immunologic considerations, general, *Feb.*, 77–9
Immunologic immaturity, *Feb.*, 78
Immunologic properties of somatotropin, *May*, 442–4
Immunologic tolerance, *Feb.*, 22, 23
Immunosuppression after renal transplantation, *May*, 391–4
rejection after, *May*, 394
Impedance plethysmography, *Aug.*, 779
Impetigo as contraindication to smallpox vaccination, *Feb.*, 92
Imuran. See *Azathioprine.*
Inborn errors of metabolism. See under *Metabolism.*
Incurvation of trunk in newborn, *Aug.*, 828, 829
Infancy
hemolytic anemias of, *Aug.*, 886
thalassemia major in, *Aug.*, 898–9
Infantile coarctation of aorta, *Feb.*, 129
Infantile hypercalcemia, *May*, **503–25**
Infantile lactic acidosis, familial. See under *Acidosis.*
Infantile pyknocytosis, *Aug.*, 888–9
Infants. See also *Newborn; Premature infants.*
anencephalic, steroids in, *Feb.*, 65
giant, hypoglycemia in, *Aug.*, 912

Infants (*Continued*)
of diabetic mothers, hypoglycemia in, *Aug.*, 912–13
sick, transportation of, *Aug.*, 725
Infection. See also *Immunity.*
cytomegalovirus. See *Cytomegalovirus infection.*
hemolytic anemias of newborn associated with, *Aug.*, 887–8
rubella, transplacental, *May*, 255–8
Infectious disease, psychologic factors and resistance to, *May*, **315–35**
Inheritance. See *Heredity.*
Inspiratory reserve volume, *Aug.*, 778
Insulin
for hyperkalemia in newborn, *Aug.*, 764
growth hormone and, *May*, 448
Intelligence quotient, effect of hypoglycemia on, *Aug.*, 916
Interaction of nutrition and genetics in timing of growth and development, *May*, **353–79**
Interferon in resistance to viral infections, *May*, 317
Intracranial hemorrhage and hyaline membrane disease, *Aug.*, 688
Intrauterine environment. See under *Environment.*
Iodine. See also *Goiter; Thyroid.*
butanol-extractable, in lymphocytic thyroiditis, *Feb.*, 28, 29
protein-bound, in lymphocytic thyroiditis, *Feb.*, 28, 29
Irradiation. See *Radiation.*
Islet cell adenomas, hypoglycemia due to, *Aug.*, 912
Isolated pulmonic stenosis, *Feb.*, 108–17

KANAMYCIN
therapeutic use, *May*, 237–8
in newborn, *May*, 536–7
Keflin. See *Cephalothin.*
Kernicterus in hemolytic anemias, *Aug.*, 887
Kidneys
effect of somatotropin on, *May*, 447
function
after renal transplantation, *May*, 400
in drug excretion in newborn, *May*, 533, 534
in hemolytic-uremic syndrome, *May*, 298
maturity, assessment of, *Aug.*, 857
necrosis, cortical, in hemolytic-uremic syndrome, *May*, 301
transplantation, *May*, 382–405
azathioprine toxicity, *May*, 396–7
death, causes of, *May*, 396
donor selection, *May*, 383–5
ethical issues, *May*, 386–7
histocompatibility tests, *May*, 385–6
immunosuppression, *May*, 391–4
mortality after, *May*, 400
pathologic studies, *May*, 400–405
pediatric problems, *May*, 397–9

Kidneys (*Continued*)
transplantation
postoperative care, *May*, 391
rehabilitation after, *May*, 400
rejection
late, *May*, 396
with immunosuppression, *May*, 394
renal function after, *May*, 400
splenectomy, *May*, 399
survival after, *May*, 400
technical problems, *May*, 388–91
thymectomy, *May*, 399
tissue preservation, *May*, 387–8
tubular reabsorption of sodium, defect in, *Feb.*, 54
Wilms's tumor, vs. neuroblastoma, *Feb.*, 7
Knee, skeletal development, *May*, 366

LABOR. See also *Delivery; Newborn; Placenta; Pregnancy;* etc.
complications, relation to respiratory distress syndrome, *Aug.*, 674
effects on fetal heart rate, *Aug.*, 759–61
fetal heart rate during, *Aug.*, 653
influence on fetus and newborn, *Aug.*, **575–98**
mechanical effects, *Aug.*, 591–2
sensory input to fetus during, *Aug.*, 652
Laboratory
aids, early use in newborn, *Aug.*, 666
data
in aortic stenosis, *Feb.*, 121–4
in atrial septal defect, *Feb.*, 151–4
in coarctation of aorta, *Feb.*, 131–4
in endocardial cushion defects, *Feb.*, 171–4
in lymphocytic thyroiditis, *Feb.*, 28–30
in patent ductus arteriosus, *Feb.*, 141–4
in pulmonic stenosis, *Feb.*, 111–14
in tetralogy of Fallot, *Feb.*, 191–4
in transposition of great vessels, *Feb.*, 201–204
in transposition of pulmonary veins, *Feb.*, 181–4
in tricuspid atresia, *Feb.*, 211–14
in ventricular septal defect, *Feb.*, 161–4
findings in hypercalcemia, *May*, 509–10
Lactic acidosis. See under *Acidosis.*
Lactogen, placental, *May*, 449
Law
Boyle's, *Aug.*, 780
Hooke's, *Aug.*, 770
Ohm's, *Aug.*, 775
Length, body, relation to gestational age, *Aug.*, 851–2
Leukemia
cytogenetic abnormalities in, *May*, 274
etiology, epidemiologic evidence, *May*, **267–77**
genetic disease before onset of, *May*, 272–3
in twins, concordance rates, *May*, 273
Leukocytes in hemolytic-uremic syndrome, *May*, 300

Leukodystrophy, metachromatic, *May*, 488
clinical features, *May*, 495
Lincocin. See *Lincomycin.*
Lincomycin (Lincocin), therapeutic use, *May*, 238
Lipid metabolism, effect of somatotropin on, *May*, 446–7
Lipidosis, sulfatide. See *Leukodystrophy, metachromatic.*
Liver
in respiratory distress, *Aug.*, 685
transplantation, *May*, 405–19
auxiliary, *May*, 412–19
orthotopic, *May*, 405–12
Lungs. See also *Respiration; Thorax;* etc.
blood flow
and vascular resistance, *Aug.*, 693–8
in respiratory distress syndrome, *Aug.*, 695–8
in respiratory distress syndrome, *Aug.*, **693–701**
increased, with left-to-right shunts, *Aug.*, 695–6
reduced, with right-to-left shunts, *Aug.*, 696–8
support of, for respiratory distress syndrome, *Aug.*, 723–4
capillaries, in respiratory distress syndrome, *Aug.*, 698–9
capillary blood volume, *Aug.*, 789
clearance delay, *Aug.*, 784, 785
compliance, *Aug.*, 770–74
dynamic, *Aug.*, 773
specific, *Aug.*, 771
total, *Aug.*, 771, 774
dead space, *Aug.*, 782–4
diffusing capacity, *Aug.*, 788–90
measurements and interpretation, *Aug.*, 789–90
theory and methods, *Aug.*, 788–9
diffusion, *Aug.*, 788–90
dynamics, *Aug.*, 774–8
measurements and interpretation, *Aug.*, 777–8
theory and methods, *Aug.*, 774–7
effect of oxygen on, *Aug.*, 740
expansion, stability of, relation to survival time, *Aug.*, 704
function
mechanics, *Aug.*, 770–78
neonatal, *Aug.*, 769–99
purpose, *Aug.*, 770
statics, *Aug.*, 770–74
sympathetic activity in, *Aug.*, 866
maturity, assessment of, *Aug.*, 856–7
pathology, in respiratory distress syndrome, *Aug.*, **703–10**
perfusion, *Aug.*, 790
nonuniformity, *Aug.*, 791–6
pressure work, *Aug.*, 776
pressure-volume curves, *Aug.*, 770–74
reflexes, *Aug.*, 814–17
excitation, *Aug.*, 815
location, *Aug.*, 814
physiologic significance, *Aug.*, 815
response, *Aug.*, 815
Lungs (*Continued*)
residual capacity, functional, *Aug.*, 778–81
resistance, *Aug.*, 774–8
total, *Aug.*, 776
statics
measurement and interpretation, *Aug.*, 773–4
theory and methods, *Aug.*, 770–73
structural and surface tension changes, *Aug.*, 703–10
structure, relation to respiratory distress syndrome, *Aug.*, 705–707
surfactant, *Aug.*, 703, 770–74
ventilation, *Aug.*, 778–88
nonuniformity, *Aug.*, 791–6
ventilation-perfusion ratio, *Aug.*, 791
vital capacity, crying, *Aug.*, 779
volumes, *Aug.*, 781
dynamic, *Aug.*, 782–4
measurements and interpretation, *Aug.*, 783
theory and methods, *Aug.*, 782–3
expiratory reserve, *Aug.*, 778
inspiratory reserve, *Aug.*, 778
residual, *Aug.*, 778–81
static, *Aug.*, 778–81
measurements and interpretation, *Aug.*, 780–81
theory and methods, *Aug.*, 778–80
tidal, *Aug.*, 778–81
total, *Aug.*, 778–81
Lymphocytic thyroiditis. See under *Thyroiditis.*
Lysine intolerance, congenital, with periodic ammonia intoxication, *May*, 484
clinical features, *May*, 495

McCARTHY reflex in newborn, *Aug.*, 827, 829
Magnesium sulfate enema for respiratory distress syndrome, *Aug.*, 722
Malabsorption
methionine, syndrome of, *May*, 473–4
tryptophan, *May*, 477
Maladie de Roger, *Feb.*, 160
Malformations. See *Abnormalities.*
Malnutrition. See also *Nutrition.*
fetal, relation to gestational age, *Aug.*, 836, 838
role in mental retardation, *May*, 479
Maneuver
heel-to-ear, in newborn, *Aug.*, 826, 829
scarf, in newborn, *Aug.*, 826–7, 829
Valsalva's, *Aug.*, 804, 805
Marfan's syndrome
genetics, *May*, 340
vs. homocystinuria, *May*, 470
Massage
cardiac, for asphyxia, *Aug.*, 625
carotid sinus, *Aug.*, 804
Maternal blood flow, effect of stress and pharmacologic agents on, *Aug.*, 758–9
Maternal cardiovascular adjustments in pregnancy, *Aug.*, 753–4

Maternal complications, relation to respiratory distress syndrome, *Aug.*, 674–5
Maternal factors in fetal and neonatal asphyxia, *Aug.*, 582–4
Maternal hemodynamic changes during labor, *Aug.*, 576
Maternal medications, effect on newborn, *Aug.*, 659–62
Maternal-fetal-placental interrelations involving steroid hormones, *Feb.*, **59–73**
Maturity, respiratory distress syndrome and, *Aug.*, 704–705
Measles immunization, *Feb.*, 81, 98–9
Meat-base formula in hypercalcemia, *May*, 516
Mechanical effects of labor, *Aug.*, 591–2
Mechanics, *Aug.*, 770
  of pulmonary function, *Aug.*, 770–78
  respiratory, *Aug.*, 775
Medications. See *Drugs.*
Medicine, preventive, in newborn, *Aug.*, **651–68**
Membranes, hyaline. See *Hyaline membranes.*
Mental deficiency, self-mutilation and choreo-athetosis, hyperuricemia with, *May*, 486, 495
Mental retardation
  in hypercalcemia, *May*, 509
  role of malnutrition in, *May*, 479
Mepivacaine (Carbocaine), effect on fetus and newborn, *Aug.*, 591
Metabolic action of somatotropin, *May*, 444–8
Metabolism. See also *Heat production;* and under specific substances.
  catecholamine, in neuroblastoma, *Feb.*, 9
  disorders, inherited, hypoglycemia due to, *Aug.*, 911
  erythrocyte, in newborn, *Aug.*, 881–5
  fat, in newborn, *Aug.*, 867
  inborn errors
    clinical features, *May*, 494–6
    future of studies on, *May*, 493
    newer, *May*, **469–501**
  of newborn, factors influencing, *Aug.*, 610–14
Metachromatic leukodystrophy. See under *Leukodystrophy.*
Metanephrine, *Feb.*, 4
Methasone-treated asthmatics, metyrapone test in, *May*, 547, 551
Methemoglobin formation in erythrocytes of newborn, *Aug.*, 884–5
Methicillin
  therapeutic use, *May*, 241, 242
    in newborn, *May*, 538
Methionine
  effect on tryptophan metabolism, *May*, 473
  for acidification of urine, *May*, 240
  malabsorption syndrome, *May*, 473–4
    clinical features, *May*, 494
  metabolism in homocystinuria, *May*, 470
Methioninemia, *May*, 472
Methisazone for smallpox, *Feb.*, 91
Metyrapone, *May*, 543
  abnormal response to, factors in, *May*, 552
  failure to respond to, significance, *May*, 552
  test in ACTH-cortisol insufficiency, *May*, 545–6, 548–51
Milk elimination in hypercalcemia, *May*, 516
Mineral metabolism, effect of somatotropin on, *May*, 445–6
Mineralocorticoids, postoperative use in primary hyperaldosteronism, *Feb.*, 51
Mongolism. See *Down's syndrome.*
Morbidity, neonatal, *Aug.*, 656–64
Moro reflex in newborn, *Aug.*, 827, 829
Mortality
  neonatal, Apgar scores and, *Aug.*, 636–8
  operative
    in aortic stenosis, *Feb.*, 126
    in atrial septal defect, *Feb.*, 156
    in coarctation of aorta, *Feb.*, 136
    in endocardial cushion defects, *Feb.*, 176
    in patent ductus arteriosus, *Feb.*, 146
    in pulmonic stenosis, *Feb.*, 116
    in transposition of great vessels, *Feb.*, 206
    in transposition of pulmonary veins, *Feb.*, 186
    in tricuspid atresia, *Feb.*, 216
    in ventricular septal defect, *Feb.*, 166
Mothers, diabetic, infants of, hypoglycemia in, *Aug.*, 912–13
Motility in newborn, *Aug.*, 826, 829
Murmurs, cardiac. See *Heart, murmurs and sounds.*
Muscles
  neck, in newborn, *Aug.*, 827, 829
  tone in newborn, evaluation, *Aug.*, 826–7, 829
Muscular dystrophy. See under *Dystrophy.*
Mutilation, self-, choreo-athetosis and mental deficiency, hyperuricemia with, *May*, 486, 495
Myocardium. See also *Heart.*
  function, sympathetic activity in, *Aug.*, 866–7

NAFCILLIN (Unipen), therapeutic use, *May*, 243
Nalidixic acid (NegGram)
  dosage, *May*, 239
  therapeutic use, *May*, 238–9
Neck muscles in newborn, *Aug.*, 827, 829
Necrotizing encephalopathy, lactic acidosis with, *May*, 491, 496
NegGram. See *Nalidixic acid.*
Neomycin
  dosage, *May*, 240
  therapeutic use, *May*, 239–40
    in newborn, *May*, 536–7
Neonatal. See also *Newborn.*
  factors in asphyxia, *Aug.*, 585
  life, role of thermal factors in, *Aug.*, **599–619**
  pharmacology, May, **527–41**

Nephritis, glomerular, in hemolytic-uremic syndrome, *May*, 301
Nervous system. See also *Brain; Reflex;* etc.
central, effects of cytomegalovirus infection on, *May*, 283–5
maturity, assessment of, *Aug.*, 858
sympathetic
activity
in newborn, *Aug.*, 863–77
in respiratory distress syndrome, *Aug.*, 872–3
overactivity, *Aug.*, 868–73
clinical disorders due to, *Aug.*, 869
pharmacology, *Aug.*, 864
Neural control of pituitary function, *May*, 429, 430
Neural tumors
chronic diarrhea and, *Feb.*, 13
functioning, *Feb.*, **3–18**
Neuroblastoma, *Feb.*, 4–11
catecholamine metabolism, *Feb.*, 9
Neuroendocrine regulation of sexual function and growth, *May*, **423–36**
Neurologic abnormalities
Apgar score and birth weight, *Aug.*, 638–40
due to hypoglycemia, *Aug.*, 916
Neurologic evaluation of fetal age, *Aug.*, **823–33**
findings, *Aug.*, 829
history, *Aug.*, 823–4
limitations, *Aug.*, 824–5
purpose, *Aug.*, 823–4
terms, definition of, *Aug.*, 825–6
Newborn. See also *Premature infants.*
acid-base state, effects of cold on, *Aug.*, 608
Apgar score, *Aug.*, 593, **645–50**
apnea due to drugs administered to mother, *Aug.*, 589
asphyxia, causes of, *Aug.*, 582–5
baroreceptor reflexes, *Aug.*, 804–805
cardiopulmonary adaptation, integrated, *Aug.*, 794–6
cardiovascular and respiratory reflexes, *Aug.*, **801–21**
cardiovascular adjustments, *Aug.*, 764–5
central chemoreceptors, *Aug.*, 813–14
changes in body temperature, *Aug.*, 605–608
chemoreceptor reflexes, aortic and carotid bodies, *Aug.*, 807–809
circulation, transitional, *Aug.*, 761–2
condition, evaluation of, *Aug.*, 592–3
cry, *Aug.*, 829
drug absorption, *May*, 528–9
drug distribution, *May*, 529–31
drug excretion, *May*, 533–4
drug metabolism, *May*, 531–3
effect of maternal medications on, *Aug.*, 659–62
effect of pain relief on, *Aug.*, 589–91
electroencephalogram, *Aug.*, 828–32
energy substrates, *Aug.*, 867–8
erythrocytes. See under *Erythrocytes.*
exposure to cold, effects of, *Aug.*, 616
Newborn (*Continued*)
fat metabolism, *Aug.*, 867
growth-retarded, measurements in, *Aug.*, 850
heat loss, *Aug.*, 605
heat production, *Aug.*, 608
sites of, *Aug.*, 602
hemolytic anemias unrelated to isoimmunization, *Aug.*, 886–99
hyperkalemia, circulatory effects of, *Aug.*, 763–4
hypoglycemia, *Aug.*, **905–20**
immature, *Aug.*, 656–7
influence of labor on, *Aug.*, **575–98**
intensive care, *Aug.*, 725–6
metabolism, factors influencing, *Aug.*, 610–14
minimal use of procedures in first and second reactivity periods, *Aug.*, 666–7
morbidity, *Aug.*, 656–64
mortality, Apgar scores and, *Aug.*, 636–8
muscular tone, evaluation of, *Aug.*, 826–7, 829
onset of breathing and resuscitation, *Aug.*, **621–34**
outcome in relation to Apgar score, *Aug.*, **635–43**
oxygen consumption, and relation to body temperature, *Aug.*, 608–10
oxygen therapy for, *Aug.*, **731–52**
pulmonary function, *Aug.*, **769–99**
pulmonary reflexes, *Aug.*, 815
reaction to delivery, *Aug.*, 652–6
reactivity after delivery, *Aug.*, 655, 656
reflexes, *Aug.*, 827–8, 829
respiratory difficulty, clinical diagnosis of, *Aug.*, **669–92**
responses to hypoxia, *Aug.*, 737, 738
sympathetic activity in, *Aug.*, 863–77
symposium on, *Aug.*, **573–920**
thermoregulation, *Aug.*, 605–17
transition, complicated, *Aug.*, 656–64
transitional care, *Aug.*, 651–68
with low Apgar score, *Aug.*, 657–9
Nicotinic acid in Hartnup disease, *May*, 477
Nitrofurantoin (Furadantin), therapeutic use, *May*, 240
Nitrogen pressure differences, alveolar-arterial, *Aug.*, 791
Nodule, breast, size of, relation to gestational age, *Aug.*, 842
Nonspherocytic hemolytic anemia, congenital, in newborn, *Aug.*, 893–4
Norepinephrine, *Feb.*, 3, 4
effect on pulmonary function in newborn, *Aug.*, 866
excretion
in neuroblastoma, *Feb.*, 9
in pheochromocytoma, *Feb.*, 15
postoperative use for pheochromocytoma, *Feb.*, 16
sympathetic activity, *Aug.*, 864
in fetus, *Aug.*, 864, 865
in placenta, *Aug.*, 864, 865
Normetanephrine, *Feb.*, 4
excretion in neuroblastoma, *Feb.*, 9

Novobiocin, therapeutic use in newborn, *May*, 537
Nursery
  routine, modification of, *Aug.*, 664–7
  transitional care, *Aug.*, **651–68**
Nutrition. See also *Malnutrition; Metabolism;* etc.
  and genetics, interaction of, in timing of growth and development, *May*, **353–79**

OASTHOUSE urine disease, *May*, 473
Ocular. See *Eyes.*
Ohm's Law, *Aug.*, 775
Operable congenital heart disease, *Feb.*, **105–219**
Organ transplantation, *May*, **381–422**
Ossification, epiphysial, relation to gestational age, *Aug.*, 839
Osteogenesis imperfecta, genetics, *May*, 345
Ostium primum atrial septal defect, *Feb.*, 168
Oxacillin (Prostaphlin)
  therapeutic use, *May*, 242
    in newborn, *May*, 538
Oximeters, ear, for measurement of oxygen concentration, *Aug.*, 742
Oxygen. See also *Respiration.*
  administration, methods of, *Aug.*, 743–4
  clinical uses, *Aug.*, 744–9
    monitoring of, *Aug.*, 741–3
      indirect, *Aug.*, 742–3
      methods, *Aug.*, 741–2
    problems in, *Aug.*, 750
    suggestions for, *Aug.*, 749
  consumption. See also *Metabolism.*
    by placenta, *Aug.*, 586
    for measurement of oxygen concentration, *Aug.*, 742, 743
    of newborn and relation to body temperature, *Aug.*, 608–10
  differences, alveolar-arterial, *Aug.*, 793
  hemoglobin binding, *Aug.*, 733
  hyperbaric
    for respiratory distress syndrome, *Aug.*, 720–21
    for resuscitation, *Aug.*, 628
  partial pressures in alveolar air and arterial and capillary blood, *Aug.*, 735
  pressure differences, alveolar-arterial, *Aug.*, 792
  pulmonary diffusing capacity, *Aug.*, 788–90
  saturation of fetal blood, *Aug.*, 757
  tension, arterial, in initiation of breathing, *Aug.*, 622
  therapy
    for newborn, *Aug.*, **731–52**
    for relief of fetal distress, *Aug.*, 587, 588
    for respiratory distress syndrome, *Aug.*, 718–21
    physiologic basis, *Aug.*, 732–8
  toxicity, *Aug.*, 738–41
  transfer across placenta, *Aug.*, 586–8
  unsaturation, arterial, in respiratory distress, *Aug.*, 685
Oxygen-carrying capacity of fetal blood, *Aug.*, 580
Oxygenation
  fetal, *Aug.*, 579–80
  of fetal blood, *Aug.*, 754, 755

PAIN relief, effect on fetus and newborn, *Aug.*, 589–91
Parenteral fluid therapy. See under *Fluids.*
Parents
  genetic counseling, *May*, 337–52
  height, specific standards, *May*, 357, 358
  mating types and progeny, *May*, 340
Patent ductus arteriosus, *Feb.*, 138–47
Pathologist, evaluation of fetal age, *Aug.*, **849–62**
Pathology, pulmonary, in respiratory distress syndrome, *Aug.*, **703–10**
PBI. See *Iodine, protein-bound.*
Pediatric problems after renal transplantation, *May*, 397–9
Penicillin. See also *Ampicillin; Cloxacillin; Dicloxacillin; Diphenicillin; Nafcillin; Oxacillin.*
  therapeutic use, *May*, 240–45
    in newborn, *May*, 537–8
Pentose-phosphate shunt in erythrocytes of newborn, *Aug.*, 882
Perfusion, pulmonary, *Aug.*, 790
Perinatal circulation, *Aug.*, **753–67**
Peritoneal dialysis in hemolytic-uremic syndrome, *May*, 306
Pertussis immunization, *Feb.*, 81, 82–4
Pharmacologic agents, effect on blood flow, *Aug.*, 758–9
Pharmacology, neonatal, *May*, **527–41**
Phenothiazines, administration to mother, effect on newborn, *Aug.*, 660, 661
Phenotype, *May*, 339
Phentolamine (Regitine), diagnostic use in pheochromocytoma, *Feb.*, 15
Pheochromocytoma, *Feb.*, 13–16; *Aug.*, 869
Phosphate metabolism, effect of somatotropin on, *May*, 446
Physical handicap, delinquency due to, *May*, 462–3
Physicians, iatrogenic ACTH-cortisol insufficiency, duration of, *May*, **543–57**
Physicochemical properties of somatotropin, *May*, 442–4
Physiologic dead space, *Aug.*, 782
Physiologic response to psychologic stress, *May*, 321–3
Pink disease, *Aug.*, 869
Pituitary
  dwarfism, somatotropin for, *May*, 449, 450
  function, neural control, *May*, 429, 430
PL. See *Lactogen, placental.*
Placenta
  dissipation of fetal heat through, *Aug.*, 604
  oxygen consumption, *Aug.*, 586
  oxygen transfer across, *Aug.*, 586–8
  sympathetic activity in, *Aug.*, 864–5
  transplacental infection, rubella, *May*, 255–8

Placenta (*Continued*)
transport of maternal corticosteroids, *Feb.*, 68–9
Placental factors in fetal and neonatal asphyxia, *Aug.*, 584
Placental lactogen, *May*, 449
Placental transfusion and respiratory distress, *Aug.*, 628–31
Placental-fetal endocrine relation, *Feb.*, 67–9
Placental-maternal-fetal interrelations involving steroid hormones, *Feb.*, **59–73**
Plasma. See also *Blood.*
umbilical cord, steroids in, measurement, *Feb.*, 63–4
Plethysmography, *Aug.*, 778, 779
Pneumothorax, oxygen for, *Aug.*, 745
Points cardinaux, *Aug.*, 827
Poliomyelitis
immunity, rapidity, after vaccination, *Feb.*, 94–5
immunization, *Feb.*, 81, 93–8, 99–102
of unvaccinated, *Feb.*, 95
Poliovirus vaccines, *Feb.*, 93, 99–102
antibody response to, *Feb.*, 94
dosage, *Feb.*, 97–8
ease of administration, *Feb.*, 95
effectiveness, *Feb.*, 95
for prevention of epidemics, *Feb.*, 96
immunity, durable, *Feb.*, 97
resistance to reinfection, *Feb.*, 95
risk, *Feb.*, 100, 101
safety, *Feb.*, 96
Polymyxin B
therapeutic use, *May*, 245, 246
in newborn, *May*, 536
Polymyxin E. See *Colistimethate.*
Polymyxins, therapeutic use, *May*, 245–6
Popliteal angle in newborn, *Aug.*, 826, 829
Position, body, for prevention of respiratory distress syndrome, *Aug.*, 716
Postoperative care after renal transplantation, *May*, 391
Posture in newborn, *Aug.*, 826, 829
Postvaccinal encephalitis, *Feb.*, 93
Potassium
depletion in hyperaldosteronism, *Feb.*, 49, 50
metabolism, effect of somatotropin on, *May*, 445
preoperative use in primary hyperaldosteronism, *Feb.*, 51
Prednisone
after renal transplantation, *May*, 393
for hypoaldosteronism, *Feb.*, 56
Prednisone-treated asthmatics, metyrapone test in, *May*, 547, 551
Pregnancy. See also *Fetus; Labor;* etc.
complications, relation to respiratory distress syndrome, *Aug.*, 674
maternal cardiovascular adjustments in, *Aug.*, 753–4
uterine blood flow during, *Aug.*, 754
Pregnenolone, biosynthesis, *Feb.*, 61
Prehensile grasp, abnormal, *Aug.*, 640
Premature infants
acidosis, oxygen for, *Aug.*, 748–9
Premature infants (*Continued*)
cardiac murmurs, *Aug.*, 764
somatotropin for, *May*, 451
Prematurity
atelectasis of, *Aug.*, 705
prevention, for prevention of respiratory distress syndrome, *Aug.*, 714–15
Pressure work, pulmonary, *Aug.*, 776
Pressure-volume curves, pulmonary, *Aug.*, 770–74
Preventive medicine in newborn, *Aug.*, **651–68**
Primary reaction to smallpox vaccination, *Feb.*, 91
Procaine chloride for tissue preservation in renal transplantation, *May*, 387
Procedures, minimal use during first and second reactivity periods in newborn, *Aug.*, 666–7
Progesterone, biosynthesis, *Feb.*, 61
Prolinemia, clinical features, *May*, 495
Prostaphlin. See *Oxacillin.*
Proteins. See also *Amino acids; Nitrogen.*
binding of drugs, *May*, 530
synthesis in growth promotion, *May*, 445
Psychogenic diseases, *May*, 319
Psychologic factors
and resistance to infectious disease, *May*, **315–35**
in etiology of disease, *May*, 318–20
Psychologic stress. See under *Stress.*
Psychosis, delinquency as manifestation of, *May*, 466–7
Puberty
precocious, *May*, 424, 425
etiology, *May*, 426
mechanism, *May*, 426–7
pseudoprecocious, *May*, 425
timing of, *May*, 427
Public health aspects of hypercalcemia, *May*, 522–3
Pulmonary. See also *Lungs.*
circulation. See under *Blood circulation.*
fluid in fetus, *Aug.*, 621–2
veins, transposition, complete, *Feb.*, 178–87
Pulmonic stenosis, isolated, *Feb.*, 108–17
Pupillary response in newborn, *Aug.*, 827, 829
Pyknocytosis, infantile, *Aug.*, 888–9
Pyridoxine deficiency or dependency, *May*, 476
Pyruvate-kinase deficiency in newborn, *Aug.*, 896

QUERVAIN'S disease, *Feb.*, 20
Quervain's thyroiditis, *Feb.*, 19
Quotient, intelligence, effect of hypoglycemia on, *Aug.*, 916

RADIATION
after renal transplantation, *May*, 394
dissipation of thermal energy by, *Aug.*, 603
intrauterine leukemia due to *May* 268–9

Radiation (*Continued*)
leukemia due to, *May*, 267–70
partial-body, leukemia due to, *May*, 268
preconception, leukemia due to, *May*, 269–70
therapy
for ganglioneuroblastoma, *Feb.*, 12
for neuroblastoma, *Feb.*, 9, 10
whole-body, leukemia due to, *May*, 267–8
Radiotherapy. See *Radiation therapy.*
Radiologic. See *Roentgen.*
Rauwolfia, administration to mother, effect on newborn, *Aug.*, 660
R.D.S. See *Respiratory distress syndrome.*
Reactions
Shwartzman, *May*, 302, 303
to smallpox vaccination, *Feb.*, 91–2
Reactivity of newborn after delivery, *Aug.*, 655, 656
Recoil in newborn, *Aug.*, 826, 829
Redressement du tronc, *Aug.*, 828, 829
Reflex
chemoreceptor, *Aug.*, 805–14
Head's, *Aug.*, 814, 815
Hering-Breuer, *Aug.*, 815
in newborn, *Aug.*, 827–8, 829
pulmonary, *Aug.*, 814–17
sino-aortic baroreceptor, *Aug.*, 801–805
Regional anesthesia, effect on newborn, *Aug.*, 590–91
Regitine. See *Phentolamine.*
Rehabilitation after renal transplantation, *May*, 400
Renal. See *Kidneys.*
Respiration
initiation, *Aug.*, 622–4
mechanics, *Aug.*, 775
normal, mechanisms necessary for, *Aug.*, 669, 670, 671
rate, in respiratory distress, *Aug.*, 677 ff.
Respiratory and cardiovascular reflexes in newborn, *Aug.*, **801–21**
Respiratory compliance, total, *Aug.*, 771, 774
Respiratory difficulty
due to cesarean section, *Aug.*, 593
in newborn, clinical diagnosis, *Aug.*, **669–92**
Respiratory distress
mild to moderate, *Aug.*, 676–7
placental transfusion and, *Aug.*, 628–31
severe, *Aug.*, 677–89
syndrome
Apgar score and, *Aug.*, 673–4
birth weight and, *Aug.*, 675–6
clinical manifestations, *Aug.*, 676–89
delivery and, *Aug.*, 674–5
diagnosis, *Aug.*, 689
criteria for, *Aug.*, 673
gestational age and, *Aug.*, 675–6
hyperbilirubinemia complicating, *Aug.*, 724–5
idiopathic, *Aug.*, 672–89
intensive care, *Aug.*, 725–6
maternal complications and, *Aug.*, 674–5
maturity and, *Aug.*, 704–705
oxygen for, *Aug.*, 745–8
Respiratory distress (*Continued*)
syndrome, prevention, *Aug.*, 714–17
and treatment, *Aug.*, **711–30**
by oxygen therapy, *Aug.*, 732
measures proposed, *Aug.*, 713
pulmonary blood flow and vascular resistance in, *Aug.*, 695–8
pulmonary capillaries in, *Aug.*, 698–9
pulmonary circulation in, *Aug.*, **693–701**
pulmonary pathology, *Aug.*, **703–10**
relation of lung structure to, *Aug.*, 705–707
relation to gestational age, *Aug.*, 836, 838
roentgenography, *Aug.*, 689
selection of patients for treatment, *Aug.*, 711–12
sex and, *Aug.*, 676
survival
relation to hyaline membranes, *Aug.*, 704
relation to stability of pulmonary expansion, *Aug.*, 704
sympathetic activity in, *Aug.*, 872–3
transportation of infant to medical center, *Aug.*, 725
treatment, *Aug.*, 717–24
evaluation, *Aug.*, 712–14
proposed measures, *Aug.*, 713
transitional, *Aug.*, 676
Respiratory responses during asphyxia and resuscitation, *Aug.*, 624–7
Response, diminished, in respiratory distress, *Aug.*, 685, 686
Resuscitation. See also *Asphyxia; Heart, massage;* etc.
and breathing, onset, *Aug.*, **621–34**
cardiovascular responses during, *Aug.*, 624–7
hyperbaric oxygen for, *Aug.*, 628
hypothermia and, *Aug.*, 627–8
oxygen for, *Aug.*, 744
respiratory responses during, *Aug.*, 624–7
Retardation
developmental, delinquency due to, *May*, 461–2
mental. See *Mental retardation.*
Reticuloendothelial system in hemolytic-uremic syndrome, *May*, 300
Reticuloendotheliosis vs. neuroblastoma, *Feb.*, 7
Reticulum cell sarcoma vs. neuroblastoma, *Feb.*, 7
Retina, effect of oxygen on, *Aug.*, 739–40
Retraction
chest, in respiratory distress syndrome, *Aug.*, 681, 683
score, Silverman, *Aug.*, 683
Retrolental fibroplasia, *Aug.*, 731, 739
genetic counseling in, *May*, 347
Riedel's struma, *Feb.*, 20
Riedel's thyroiditis, *Feb.*, 19
Ringer's solution for tissue preservation in renal transplantation, *May*, 387
Roentgen examination
for neuroblastoma, *Feb.*, 7
for pheochromocytoma, *Feb.*, 15

Roentgen examination (*Continued*)
in aortic stenosis, *Feb.*, 122
in atrial septal defect, *Feb.*, 152
in coarctation of aorta, *Feb.*, 132
in endocardial cushion defects, *Feb.*, 172
in patent ductus arteriosus, *Feb.*, 142
in pulmonic stenosis, *Feb.*, 112
in respiratory distress, *Aug.*, 689
in tetralogy of Fallot, *Feb.*, 192
in transposition of great vessels, *Feb.*, 202
in transposition of pulmonary veins, *Feb.*, 182
in tricuspid atresia, *Feb.*, 212
in ventricular septal defect, *Feb.*, 162
Roentgen findings in hypercalcemia, *May*, 510–11
Roentgen ray, rapid use as diagnostic aid in newborn, *Aug.*, 666
Rooting reflex in newborn, *Aug.*, 827, 829
Rubella, *May*, 251–66
congenital defects due to, frequency of, *May*, 252
embryopathy, prophylaxis of, *May*, 260–63
epidemiology and teratology, *May*, **251–66**
risk to fetus, *May*, 251–2
teratology and epidemiology, *May*, **251–66**
transplacental infection, *May*, 255–8
vaccines, *May*, 262–3

SABIN vaccine, *Feb.*, 93
Salk vaccine, *Feb.*, 93
Salt, dietary, for hypoaldosteronism, *Feb.*, 56
Sarcoma, reticulum cell, vs. neuroblastoma, *Feb.*, 7
Sarcosine, *May*, 476
Sarcosinemia, clinical features, *May*, 494
Saturation, oxygen, of fetal blood, *Aug.*, 757
Scarf maneuver in newborn, *Aug.*, 826–7, 829
Schick test for diphtheria, *Feb.*, 86
Schmidt's syndrome, *Feb.*, 32
Score
Apgar. See *Apgar score.*
Silverman retraction, *Aug.*, 683
Scrotum, changes, relation to gestational age, *Aug.*, 845
Section, cesarean, respiratory difficulties due to, *Aug.*, 593
Secundum type of atrial septal defect, *Feb.*, 148–57
Seizures. See *Convulsions.*
Self-mutilation, choreo-athetosis and mental deficiency, hyperuricemia with, *May*, 486, 495
Sensory input to fetus during labor and delivery, *Aug.*, 652
Septal defects. See *Atrial Septal defect; Ventricular septal defect.*
Serum. See also *Blood.*
albumin for prevention of respiratory distress syndrome, *Aug.*, 716
calcium in hypercalcemia, *May*, 510
Sex
differences in behavior, *May*, 377
incidence of lymphocytic thyroiditis, *Feb.*, 26
Sex (*Continued*)
function, neuroendocrine regulation, *May*, 423–36
relation to respiratory distress syndrome, *Aug.*, 676
Sex-linked inheritance, *May*, 342–3
vs. autosomal inheritance, *May*, 341–3
Shoulder, skeletal development, *May*, 366
Shunt, pentose-phosphate, in erythrocytes of newborn, *Aug.*, 882
Shunts. See under *Blood.*
Shwartzman reaction, *May*, 302, 303
Sickle cell disease in newborn, *Aug.*, 898
Silverman retraction score, *Aug.*, 683
Sino-aortic baroreceptor reflexes. See under *Baroreceptor reflexes.*
Sinus, carotid, massage of, *Aug.*, 804
Skeleton
development
genetic and nutritional factors, *May*, 360–67
variability, *May*, 366
growth, relation to gestational age, *Aug.*, 839, 840
Skin creases on sole of foot, relation to gestational age, *Aug.*, 842
Smallpox
immunization, *Feb.*, 81, 89–93
vaccination
complications, *Feb.*, 93
contraindications to, *Feb.*, 92
interpretation of response, *Feb.*, 91–2
Sociologic delinquency, *May*, 460–61
Sodium
bicarbonate for acidemia in respiratory distress syndrome, *Aug.*, 721
metabolism, effect of somatotropin on, *May*, 445
renal tubular reabsorption, defect in, *Feb.*, 54
Solution, Ringer's, for tissue preservation in renal transplantation, *May*, 387
Somatotropin (HGH; human growth hormone), *May*, 433–5
and adrenal hormones, *May*, 447–8
and insulin, *May*, 448
bioassays, *May*, 440
clinical experience, *May*, 449–52
concepts regarding, *May*, **437–57**
effect on mineral metabolism, *May*, 445–6
for hypoglycemia, *May*, 451–2
for idiopathic growth failure, *May*, 451
for premature infants, *May*, 451
for short stature, *May*, 449–51
growth-promoting effect, *May*, 444–5
immunoassays, *May*, 440–42
immunologic properties, *May*, 442–4
measurement, *May*, 440–42
metabolic action, *May*, 444–8
physicochemical properties, *May*, 442–4
production, *May*, 437–40
renal effects, *May*, 447
secretion, *May*, 437–40
side effects, *May*, 452
sulfation factor, *May*, 442
Somatotropin-like compounds, *May*, 448–9

Sounds, cardiac. See *Heart, murmurs and sounds.*
Spherocytosis, hereditary, neonatal manifestations, *Aug.*, 891–3
Splenectomy
for hereditary spherocytosis, *Aug.*, 891, 893
with renal transplantation, *May*, 399
Stability, thermal. See *Thermal stability.*
Statics, *Aug.*, 770
of pulmonary function, *Aug.*, 770–74
Stature, short, somatotropin for, *May*, 449–51
Stenosis
aortic, congenital, *Feb.*, 118–27
pulmonic, isolated, *Feb.*, 108–17
Steroid hormones, fetal-placental-maternal interrelations involving, *Feb.*, **59–73**
Steroids. See also *Corticosteroids.*
gonadal, role in growth and sexual function, *May*, 432–3
Stimuli
tactile, in initiation of breathing, *Aug.*, 623
thermal, in initiation of breathing, *Aug.*, 623
Stomach
aspiration for prevention of respiratory distress syndrome, *Aug.*, 716
oxygen administration for respiratory distress syndrome, *Aug.*, 720
Streptomycin
dosage, *May*, 248
therapeutic use, *May*, 247–8
in newborn, *May*, 538–9
Stress. See also *Heat; Temperature.*
effects
on blood flow, *Aug.*, 758–9
on fetal heart rate, *Aug.*, 759–61
glucocorticoid therapy in, *May*, 555
psychologic, *May*, 320–21
physiologic response to, *May*, 321–3
Stressors, *May*, 320
Struma
lymphomatosa, *Feb.*, 19, 20
Riedel's, *Feb.*, 20
Subvalvular aortic stenosis, *Feb.*, 119
Subvalvular pulmonic stenosis, *Feb.*, 109
Sucking reflex in newborn, *Aug.*, 827, 829
Sugar. See also *Carbohydrates.*
for hypoglycemia in infants of diabetic mothers, *Aug.*, 912, 913
Sulfatide lipidosis. See under *Lipidosis.*
Sulfation factor of somatotropin, *May*, 442
Sulfonamides, therapeutic use, *May*, 246–7
Supraciliary tap, *Aug.*, 827, 829
Supravalvular aortic stenosis, *Feb.*, 119
Supravalvular pulmonic stenosis, *Feb.*, 109
Surface tension of alveoli, reduction of, for respiratory distress syndrome, *Aug.*, 722
Surfactant, pulmonary, *Aug.*, 703, 770–74
nature and properties, *Aug.*, 707–708
Surgery
for aortic stenosis, *Feb.*, 126
for atrial septal defect, *Feb.*, 156
for coarctation of aorta, *Feb.*, 136
for endocardial cushion defects, *Feb.*, 176
for ganglioneuroblastoma, *Feb.*, 12
for ganglioneuroma, *Feb.*, 12
Surgery (*Continued*)
for neuroblastoma, *Feb.*, 9, 10
for patent ductus arteriosus, *Feb.*, 146
for pheochromocytoma, *Feb.*, 16
for primary hyperaldosteronism, *Feb.*, 51
for pulmonic stenosis, *Feb.*, 116
for tetralogy of Fallot, *Feb.*, 196
for transposition of great vessels, *Feb.*, 206
for transposition of pulmonary veins, *Feb.*, 186
for tricuspid atresia, *Feb.*, 216
for ventricular septal defect, *Feb.*, 166
Sympathetic activity in newborn, *Aug.*, **863–77**
Sympathomimetic amines, effect on neonatal metabolism, *Aug.*, 613
Syndrome
adrenogenital. See *Adrenogenital syndrome.*
Bartter's, *Feb.*, 53
blue diaper. See *Blue diaper syndrome.*
Down's, leukemia and, *May*, 272
formiminotransferase deficiency. See *Formiminotransferase deficiency syndrome.*
gray, *May*, 235, 535
hemolytic-uremic. See *Hemolytic-uremic syndrome.*
Hurler's, genetic causes, *May*, 344
Marfan's. See *Marfan's syndrome.*
methionine malabsorption. See under *Methionine.*
respiratory distress. See *Respiratory distress syndrome.*
rubella. See *Rubella syndrome.*
Schmidt's, *Feb.*, 32

TACHYCARDIA, fetal, *Aug.*, 760
Tactile stimuli in initiation of breathing, *Aug.*, 623
Tap, supraciliary, *Aug.*, 827, 829
Teeth
development, genetic and nutritional factors, *May*, 367–73
eruption, genetic and nutritional factors in, *May*, 369
missing, genetic and nutritional factors in, *May*, 371, 372
Tego Pen. See *Cloxacillin.*
Temperature, *Aug.*, 600
body, *Aug.*, 600
changes in neonatal period, *Aug.*, 605–608
maintenance of, *Aug.*, 599
of newborn, relation to oxygen consumption, *Aug.*, 608–10
environmental, *Aug.*, 601
neutral, *Aug.*, 600
neutral, *Aug.*, 600
regulation for respiratory distress syndrome, *Aug.*, 717
Temporal artery, use for monitoring oxygen concentration, *Aug.*, 741–2

Tension. See also *Stress.*
gas, alveolar-arterial, *Aug.*, 793
oxygen, arterial, in initiation of breathing, *Aug.*, 622
surface, of alveoli, reduction of, for respiratory distress syndrome, *Aug.*, 722
Testes, descent, relation to gestational age, *Aug.*, 845
Tests
histocompatibility, in renal transplantation, *May*, 385–6
metyrapone, in ACTH-cortisol insufficiency, *May*, 545–6, 548–51
Schick, for diphtheria, *Feb.*, 86
Tetanus
antitoxin, *Feb.*, 87, 88
gamma globulin, *Feb.*, 88, 89
immunization, *Feb.*, 81, 86–9
toxoid, *Feb.*, 87, 88
Tetracycline
dosage, *May*, 249
therapeutic use, *May*, 248–9
in newborn, *May*, 539
Tetralogy of Fallot, *Feb.*, 188–97
Thalassemia major in infancy, *Aug.*, 898–9
THAM for acidemia in respiratory distress syndrome, *Aug.*, 721
Theory, clonal selection, *Feb.*, 23
Therapy
fluid, parenteral. See under *Fluids.*
radiation. See *Radiation therapy.*
Thermal energy
dissipation, *Aug.*, 603
sources, *Aug.*, 601–603
Thermal environment, neutral, *Aug.*, 600, 807
Thermal factors, role in fetal and neonatal life, *Aug.*, **599–619**
Thermal stability, *Aug.*, 600
factors influencing, *Aug.*, 607
in newborn, impairment of, *Aug.*, 614–15
Thermal stimuli in initiation of breathing, *Aug.*, 623
Thermogenic tissues, *Aug.*, 601
Thermoregulation
of fetus, *Aug.*, 603–604
of newborn, *Aug.*, 605–17
Thiopental, effect on fetus and newborn, *Aug.*, 590
Thoracic cage compliance, *Aug.*, 771
Thoracic gas volume, *Aug.*, 780
Thorax. See also *Heart; Lungs.*
resistance, *Aug.*, 774–8
retraction, in respiratory distress syndrome, *Aug.*, 681, 683
Thrombocytopenia in hemolytic-uremic syndrome, *May*, 299, 300
Thrombosis, fibrin, of glomerular capillaries in hemolytic-uremic syndrome, *May*, 301
Thymectomy with renal transplantation, *May*, 399
Thymus in thyroid autoimmunity, *Feb.*, 24
Thyroglobulin in thyroid autoimmunity, *Feb.*, 22
Thyroid
antibodies in lymphocytic thyroiditis, *Feb.*, 31
Thyroid (*Continued*)
autoantibodies, detection, *Feb.*, 30
autoimmunity in lymphocytic thyroiditis, *Feb.*, 22–5
carcinoma, *Feb.*, 19
for lymphocytic thyroiditis, *Feb.*, 34–8
Hashimoto's disease, *Feb.*, 19, 20, 32
hormone, role in growth and sexual function, *May*, 433
hyperplasia in lymphocytic thyroiditis, *Feb.*, 21
hypothyroidism, *Feb.*, 25
Quervain's disease, *Feb.*, 20
Thyroiditis, *Feb.*, 19
diagnosis and management, *Feb.*, **19–42**
lymphocytic, *Feb.*, 20–38
age and, *Feb.*, 26
biopsy findings, *Feb.*, 31, 32
diabetes mellitus with, *Feb.*, 32
goiter in, *Feb.*, 26–7
heredity in, *Feb.*, 33
sex and, *Feb.*, 26
thyroid autoimmunity in, *Feb.*, 22–5
viruses as cause of, *Feb.*, 33–4
management and diagnosis, *Feb.*, **19–42**
Thyroidosis, *Feb.*, 19
Thyrotoxicosis, *Feb.*, 19
Tilting, effect on baroreceptor reflexes, *Aug.*, 804–805
Tissue. See also *Cells.*
preservation in renal transplantation, *May*, 387–8
thermogenic, *Aug.*, 601
transfer, mismatched, in organ transplantation, *May*, 383
Tolerance, immunologic, *Feb.*, 22, 23
Tone, muscular, in newborn, evaluation of, *Aug.*, 826–7, 829
Toxoid, tetanus, *Feb.*, 87, 88
Traction reflex in newborn, *Aug.*, 827
Transfusion. See under *Blood.*
Transfer of oxygen across placenta, *Aug.*, 586–8
Transition, complicated, in newborn, *Aug.*, 656–64
Transitional care nursery, *Aug.*, **651–68**
Transplacental infection, rubella, *May*, 255–8
Transplantation
liver. See under *Liver.*
organ, *May*, **381–422**
renal, *May*, 382–405
Transportation of sick infants, *Aug.*, 725
Transposition
of great vessels, *Feb.*, 198–207
of pulmonary veins, complete, *Feb.*, 178–87
Triamterene for Bartter's syndrome, *Feb.*, 53
Tricuspid atresia, *Feb.*, 208–17
Triose-phosphate-isomerase deficiency in newborn, *Aug.*, 897
Trunk
elevation in newborn, *Aug.*, 828, 829
incurvation in newborn, *Aug.*, 828, 829
Tryptophan
malabsorption, *May*, 477
metabolism, *May*, 476–9

Tryptophan (*Continued*)
metabolism, effect of methionine on, *May*, 473
Tryptophanemia, *May*, 478
Tryptophanuria, congenital, with dwarfism, *May*, 478
clinical features, *May*, 494
Tubules, renal, reabsorption of sodium, defect in, *Feb.*, 54
Tumors
Ewing's, vs. neuroblastoma, *Feb.*, 7
neural. See *Neural tumors.*
Wilms's, vs. neuroblastoma, *Feb.*, 7
Twins, leukemia in, concordance rates, *May*, 273
Tyrosine metabolism, *May*, 480–83
Tyrosinemia, transient, *May*, 480–81
Tyrosinosis, *May*, 482–3
clinical features, *May*, 495

UMBILICAL artery, use for monitoring oxygen concentration, *Aug.*, 741
Umbilical cord
compression, asphyxia due to, *Aug.*, 584
delayed clamping, for prevention of respiratory distress syndrome, *Aug.*, 715–16
occlusion, in initiation of breathing, *Aug.*, 623
plasma, steroids in, measurement, *Feb.*, 63–4
Unipen. See *Nafcillin.*
Urine
acidification, *May*, 240
creatinine, in ACTH-cortisol insufficiency, *May*, 545
disease, oasthouse, *May*, 473
17-hydroxycorticosteroids, in ACTH-cortisol insufficiency, *May*, 545–6, 547
Uterus
blood flow
during pregnancy, *Aug.*, 754
fetal and neonatal asphyxia due to, *Aug.*, 583–4
reduced, relief of fetal distress due to, *Aug.*, 588–9
irradiation, leukemia due to, *May*, 268–9

VACCINATION. See also *Immunity.*
sites for, *Feb.*, 82
smallpox. See under *Smallpox.*
Vaccines
combined, *Feb.*, 80
measles, *Feb.*, 99
poliovirus. See *Poliovirus vaccine.*
rubella, *May*, 262–3
Vaccinia, *Feb.*, 93
gamma globulin for, *Feb.*, 92
Vaccinoid reaction to smallpox vaccination, *Feb.*, 91
Vaginal vs. abdominal delivery, *Aug.*, 593–4
Valsalva's maneuver, *Aug.*, 804, 805
Valvular aortic stenosis, *Feb.*, 119
Valvular pulmonic stenosis, *Feb.*, 109
Vascular. See *Blood vessels.*
Vasoconstriction to reduce heat loss in newborn, *Aug.*, 606, 608
Veins, pulmonary, transposition of, complete, *Feb.*, 178–87
Ventilation. See also *Respiration.*
alveolar, *Aug.*, 782–4
control, *Aug.*, 785–8
measurement and interpretation, *Aug.*, 786–8
theory and methods, *Aug.*, 785–6
distribution, *Aug.*, 784–5
equivalent, *Aug.*, 782
pulmonary, *Aug.*, 778–88
support of, for respiratory distress syndrome, *Aug.*, 724
wasted, *Aug.*, 782
Ventricular septal defect, *Feb.*, 158–67
Vessels. See *Blood vessels.*
Viruses
cytomegaloviruses, *May*, 279
biological properties, *May*, 281–2
infection, *May*, **279–93**
central nervous system effects, *May*, 283–5
nonhuman, *May*, 281
physical-chemical properties, *May*, 281–2
properties, *May*, 281–2
ultrastructure, *May*, 282
exanthems, glucocorticoid therapy during, *May*, 555
leukemia due to, *May*, 270–72
lymphocytic thyroiditis due to, *Feb.*, 33–4
Vital capacity, crying, *Aug.*, 779
Vitamin D
allowances, *May*, 522
elimination in hypercalcemia, *May*, 516
in pathogenesis of hypercalcemia, *May*, 517, 518, 519, 520
Vitamin E deficiency, hemolytic anemia in newborn due to, *Aug.*, 889
VMA, *Feb.*, 4
excretion in neuroblastoma, *Feb.*, 9

WALKING, automatic, in newborn, *Aug.*, 828, 829
Weight
birth
neurologic abnormality and Apgar score, *Aug.*, 638–40
relation to gestational age, *Aug.*, 849–51
relation to respiratory distress syndrome, *Aug.*, 675–6
brain, relation to gestational age, *Aug.*, 852–4
parent-child correlations, *May*, 359
Wilms's tumor vs. neuroblastoma, *Feb.*, 7
Work, *Aug.*, 774, 775
pulmonary pressure, *Aug.*, 776
Wounds, tetanus prophylaxis, *Feb.*, 88

X-RAY. See *Roentgen.*